<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey Morgan, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kenneth K Tanabe, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert Maki, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonali M Shah, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 19, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Stromal or mesenchymal neoplasms affecting the gastrointestinal (GI) tract have undergone a striking evolution in how they are perceived and classified over the last 30 years. A significant breakthrough occurred with the identification of near-universal expression of the CD117 antigen by these tumors (now called gastrointestinal stromal tumors [GISTs]). The other group of spindle cell neoplasms arising in the GI tract (which are analogous to soft tissue tumors throughout the rest of the body and include lipomas, schwannomas, hemangiomas, usual leiomyomas and the malignant counterpart, leiomyosarcomas) is typically CD117-negative [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         The CD117 molecule is part of the KIT (c-kit) receptor, a membrane tyrosine kinase that is a product of the
         <em>
          KIT
         </em>
         protooncogene. In 80 percent of cases,
         <em>
          KIT
         </em>
         overexpression is the result of an activating mutation in the
         <em>
          KIT
         </em>
         protooncogene. Although the majority of GISTs are
         <em>
          KIT
         </em>
         positive, some
         <em>
          KIT
         </em>
         negative GISTs have activating mutations in a related tyrosine kinase receptor, platelet-derived growth factor receptor alpha (
         <em>
          PDGFRA
         </em>
         ). The current view is that the overwhelming majority of GI tract mesenchymal tumors fall into the GIST category; they are identifiable by KIT immunoreactivity or the presence of activating mutations in
         <em>
          KIT
         </em>
         or
         <em>
          PDGFRA
         </em>
         . (See
         <a class="medical medical_review" href="/z/d/html/7745.html" rel="external">
          "Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors", section on 'Pathogenesis'
         </a>
         .)
        </p>
        <p>
         Prior to the year 2000, there was no known effective therapy for unresectable or metastatic GISTs. It has long been appreciated that GI tract sarcomas have lower response rates to chemotherapy than other sites of soft tissue sarcomas, indicating a higher rate of primary resistance to chemotherapy in these tumors [
         <a href="#rid2">
          2-4
         </a>
         ].
        </p>
        <p>
         Treatment of GISTs was revolutionized by the finding that mutational activation of KIT or PDGFRA stimulated growth of these cancer cells. This led to effective systemic therapies in the form of small molecule inhibitors of the receptor tyrosine kinases.
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          Imatinib
         </a>
         (Gleevec), the prototype drug, was originally approved for the treatment of chronic myeloid leukemia (CML), a disorder in which an aberrant tyrosine kinase results from molecular rearrangement. (See
         <a class="medical medical_review" href="/z/d/html/4508.html" rel="external">
          "Initial treatment of chronic myeloid leukemia in chronic phase"
         </a>
         .)
        </p>
        <p>
         It subsequently became evident that molecularly targeted therapy with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         induced dramatic, rapid, and sustained clinical benefit in GISTs as well. These agents block signaling via KIT or PDGFRA by binding to the ATP-binding pocket required for phosphorylation and activation of the receptor. Other tyrosine kinase inhibitors (TKIs) have been identified that block several tyrosine kinase targets, including KIT (referred to as multitargeted TKIs). Some data suggest an anti-GIST immune response is associated with good clinical outcomes in patients with GIST on imatinib [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Here we will discuss TKI therapy for patients with advanced/metastatic GISTs. Molecular classification, clinical presentation, diagnosis, management of localized GISTS, the role of surgery in patients with metastatic disease, and the use of preoperative as well as adjuvant
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         are addressed in separate topic reviews. (See
         <a class="medical medical_review" href="/z/d/html/7745.html" rel="external">
          "Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7727.html" rel="external">
          "Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7730.html" rel="external">
          "Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          INITIAL TREATMENT BASED ON MUTATION STATUS
         </span>
        </p>
        <p class="headingAnchor" id="H2710360141">
         <span class="h2">
          Imatinib for KIT and most PDGFRA mutant GIST
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          Imatinib
         </a>
         is used as initial therapy for patients with
         <em>
          KIT
         </em>
         and most platelet-derived growth factor receptor alpha (
         <em>
          PDGFRA
         </em>
         ) mutant GIST, although GISTs associated with
         <em>
          PDGFRA
         </em>
         D842V are an exception  (
         <a class="graphic graphic_algorithm graphicRef127116" href="/z/d/graphic/127116.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Avapritinib for PDGFRA D842V mutant tumors'
         </a>
         below.)
        </p>
        <p>
         An assessment of tumor mutational status using DNA sequencing techniques is advised during the initial evaluation of patients with advanced or metastatic disease because clinical responses to
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         (and other TKIs) correlate with tumor genotype. For most patients, systemic treatment with imatinib can be initiated empirically while awaiting confirmation of tumor mutational status. Treatment may be subsequently modified once tumor mutational status becomes available. However, for those with histologies suggestive of imatinib resistance (eg, succinate dehydrogenase [SDH] deficiency or neurofibromatosis 1 [NF1]-related disease), referral to a tertiary care center for clinical trials is warranted, rather than empiric imatinib. (See
         <a class="medical medical_review" href="/z/d/html/7745.html" rel="external">
          "Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors", section on 'Diagnosis'
         </a>
         and
         <a class="local">
          'SDH-deficient tumors and those associated with NF1'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3921502826">
         <span class="h3">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Since the initial report of a patient with rapidly progressive GIST who exhibited a dramatic and sustained response within one month of starting
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         [
         <a href="#rid6">
          6
         </a>
         ], many studies have confirmed the utility of this agent in advanced disease  (
         <a class="graphic graphic_table graphicRef78415" href="/z/d/graphic/78415.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid7">
          7-11
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a phase II study, for example, 147 patients received either 400 or 600 mg of
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         daily; 54 percent had radiographic responses documented within six months, with no significant difference between the two doses [
         <a href="#rid8">
          8
         </a>
         ]. Positron emission tomography (PET) scanning proved to be a sensitive and reliable response indicator, with markedly diminished uptake, compared with baseline studies, seen in responders as early as 24 hours after the first dose of imatinib. (See
         <a class="local">
          'Assessing response to therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Adverse events were common but generally mild. These included grade 1 or 2 nausea or diarrhea in approximately one-half, fluid retention (predominantly periorbital) in three-fourths, muscle cramps and fatigue (40 and 35 percent, respectively), and gastrointestinal (GI) or intra-abdominal hemorrhage in 5 percent. (See
         <a class="local">
          'Side effects and their management'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A sizeable subset of patients in this trial survived long-term on first-line
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         . In a preliminary report of long-term follow-up of a cohort of 56 patients who continued to take imatinib beyond three years, 26 (18 percent of the initial cohort) remained on continuous imatinib since study entry at a median follow-up of 9.4 years [
         <a href="#rid12">
          12
         </a>
         ]. The overall likelihood of remaining progression-free at nine years or beyond was dependent on tumor size at initial diagnosis and ranged from 29 percent in those with an initial tumor bulk of &lt;39.1 mm
         <sup>
          2
         </sup>
         to 3 percent in those with an initial tumor bulk &gt;262.6 mm
         <sup>
          2
         </sup>
         . The corresponding rates of overall survival (OS) were 58 and 23 percent, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A similar fraction of patients with metastatic disease who achieved long-term disease control was reported in an analysis derived from the SWOG phase III S0033 trial, which studied two different dose levels of
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         (see
         <a class="local">
          'Impact of dose'
         </a>
         below). In a preliminary report presented at the 2014 American Society of Clinical Oncology (ASCO) annual meeting, 180 of the 695 eligible patients (26 percent) survived eight years or longer, and the estimated 10-year survival rate was 22 percent [
         <a href="#rid13">
          13
         </a>
         ]. Among the 137 long-term survivors, imatinib was the sole therapy administered continuously to 49 percent, while 39 percent received subsequent systemic agents including
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         and
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Following the introduction of
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         , the median survival of patients with advanced GIST increased from an average of 18 to 57 months in the trial with the longest follow-up to date [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Despite the high efficacy of
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         in most patients with metastatic/inoperable GISTs, complete responses are rare overall (less than 10 percent), and most patients who initially respond eventually acquire resistance via additional mutations in
         <em>
          KIT
         </em>
         , discussed below. The median time to progression is approximately two to three years [
         <a href="#rid8">
          8,10,15,16
         </a>
         ], although it is longer in some series [
         <a href="#rid17">
          17
         </a>
         ]. A subset of patients with metastatic GIST experiences durable responses and long-term survival with imatinib treatment [
         <a href="#rid18">
          18
         </a>
         ]. Factors influencing the duration of disease control are not well understood [
         <a href="#rid16">
          16
         </a>
         ]. (See
         <a class="local">
          'Treatment of disease refractory to imatinib'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h3">
          Assessing response to therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal method for establishing response to tyrosine kinase inhibitors (TKIs) such as
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         is evolving.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h4">
          Positron emission tomography scanning
         </span>
         <span class="headingEndMark">
          —
         </span>
         PET scans appear to identify a greater number of responses and at an earlier time than computed tomography (CT) scans [
         <a href="#rid19">
          19-23
         </a>
         ]. With functional imaging such as PET, responses can be observed within 24 hours of starting therapy, although this has little practical impact on the typical patient with metastatic GIST. In addition to detecting primary
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         resistance, PET can aid in the detection of secondary resistance, as does detection of the "nodule within a tumor" as a sign of drug resistance. (See
         <a class="local">
          'RECIST versus Choi criteria'
         </a>
         below.)
        </p>
        <p>
         If employed, a rigorous standardized approach to patient preparation and study technique is needed for reproducible results, as emphasized by consensus guidelines on use of fluorodeoxyglucose (FDG)-PET for response assessment [
         <a href="#rid24">
          24-26
         </a>
         ].
        </p>
        <p>
         The added benefit for dual modality PET/CT imaging in most cases with advanced GIST is unclear, and PET scans are rarely used to assess the response to therapy in patients with advanced disease, unless in the context of a clinical trial. Newly proposed CT criteria using either no growth in tumor size or a combination of tumor density and size criteria have shown a close correlation with the predictive value results of FDG-PET, and serial CT or MRI scanning at three- to six-month intervals is more often recommended during therapy. (See
         <a class="local">
          'Cross-sectional imaging'
         </a>
         below and
         <a class="local">
          'RECIST versus Choi criteria'
         </a>
         below.)
        </p>
        <p>
         One clinical scenario where baseline and follow-up PET scan might prove useful is for a patient with a borderline resectable GIST or a potentially resectable tumor that requires extensive organ disruption who is being treated with initial
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         [
         <a href="#rid22">
          22,27
         </a>
         ]. In these situations, early assessment of treatment response might provide an opportunity to shift to an alternative therapy (eg, resection or
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         ) if imatinib is ineffective. (See
         <a class="medical medical_review" href="/z/d/html/7730.html" rel="external">
          "Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors"
         </a>
         .)
        </p>
        <p>
         An important point is that patient symptoms also improve rapidly in the setting of response, decreasing to some degree the need to obtain imaging shortly after starting neoadjuvant
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         .
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h4">
          Cross-sectional imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Conventional CT scans with intravenous contrast enhancement are a good standard of care for radiographic assessment of most patients with metastatic GIST. Contrast-enhanced magnetic resonance imaging (MRI) also provides similar information to that obtained with contrast-enhanced CT scans.
        </p>
        <p>
         Certain finer points are worth keeping in mind based on the experience with metastatic GIST patients since the introduction of
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         . For example, GISTs will infrequently increase in size during early treatment as a consequence of intratumoral hemorrhage or myxoid degeneration. A decrease in tumor density as seen on CT (the corollary of decreased FDG uptake on PET, see above) is an important early clinical marker of antitumor activity [
         <a href="#rid28">
          28,29
         </a>
         ], as is decreased contrast uptake on standard CT or MRI scans. Once tumors become hypodense (cystic), the size of the lesions may decrease slowly and eventually stabilize.
        </p>
        <p>
         Late responses are often seen in patients who initially have stable disease, and survival in those with stable disease parallels that of patients with an objective response [
         <a href="#rid14">
          14,30
         </a>
         ]. The median time to achieve an objective response is four months, while maximal response may take six months or even longer [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         As a result of these issues, response to
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         is frequently defined as absence of progression at the time of the first formal disease re-evaluation (typically two to three months after starting therapy) [
         <a href="#rid31">
          31
         </a>
         ]. Clear-cut evidence of progression at this time point is considered initial (primary) resistance, while progression or relapse after a period of stable or responding disease is referred to as late (secondary) resistance. Initial resistance was seen in 12 percent of 934 patients in a randomized European trial exploring two different doses of imatinib (discussed below) and was more likely in patients with lung but not liver metastases (41 percent) [
         <a href="#rid15">
          15
         </a>
         ]. The management of patients with imatinib-refractory disease is discussed below. (See
         <a class="local">
          'Treatment of disease refractory to imatinib'
         </a>
         below.)
        </p>
        <p>
         For patients receiving
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         for advanced disease, the optimal interscan interval is not established. In keeping with guidelines from the National Comprehensive Cancer Network (NCCN) [
         <a href="#rid27">
          27
         </a>
         ], we perform history and physical examination, and repeat cross-sectional imaging of the abdomen and pelvis every three to six months. For patients who have low-volume or no residual detectable metastatic disease who continue to have an excellent response to imatinib, we transition to every six months imaging after three years, and then to annual imaging after six or more years.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h4">
          RECIST versus Choi criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         As noted above, radiographic response to TKIs is often indicated by an early decrease in tumor density, followed by slow tumor regression. This pattern of response is not well suited to the use of standard Response Evaluation Criteria In Solid Tumors (RECIST), which is based upon tumor measurements  (
         <a class="graphic graphic_table graphicRef74693" href="/z/d/graphic/74693.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid32">
          32,33
         </a>
         ].
        </p>
        <p>
         Likewise, disease progression in patients with GIST may also fail to be captured by standard RECIST. Tumor progression may manifest as new or enlarging tumor masses, as partial to complete filling-in of a previously hypodense lesion, or as a hyperdense "nodule-within-a-mass" pattern [
         <a href="#rid34">
          34
         </a>
         ]. The importance of identifying this latter situation is that successful ablation of such resistant clones has been reported, with continued
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         sensitivity of areas of disease that remain [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         An alternative set of response evaluation criteria has been proposed, the so-called Choi criteria [
         <a href="#rid36">
          36,37
         </a>
         ]. Investigators at MD Anderson initially showed that a 10 percent decrease in unidimensional tumor size or a 15 percent decrease in tumor density on contrast-enhanced CT scans (as reflected by differences in x-ray attenuation between a given material and water, expressed in Hounsfield units) correlates well with PET scan findings and is a better predictor of response to therapy (as judged by time to tumor progression) than standard RECIST [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         These investigators compared the Choi criteria with standard (version 1.0  (
         <a class="graphic graphic_table graphicRef74693" href="/z/d/graphic/74693.html" rel="external">
          table 2
         </a>
         )) RECIST in 98 patients (40 in a training set and 58 a test set) receiving
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         for advanced GIST who had CT scans eight weeks after starting therapy [
         <a href="#rid37">
          37
         </a>
         ]. The test set had 28 (48 percent) good responders by RECIST, compared with 49 (84 percent) good responders by Choi criteria. Even when the 98 patients were analyzed together, the response group by RECIST did not correlate significantly with either disease-specific survival or time to tumor progression, whereas the Choi response group did correlate with both endpoints. The authors concluded that tumor response for GIST should preferentially be categorized by the Choi rather than the RECIST.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Impact of dose
         </span>
         <span class="headingEndMark">
          —
         </span>
         At least two randomized trials have failed to show improved OS for higher
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         doses (800 mg daily) versus standard dosing of imatinib (400 mg daily) [
         <a href="#rid10">
          10,11
         </a>
         ]. In both trials, patients with disease progression in the standard-dose arm were allowed to cross over to high-dose therapy. The European trial demonstrated a modestly but significantly higher progression-free survival (PFS) with the 800 mg dose with median 25-month follow-up, which was no longer evident with longer follow-up (median 40 months), and which did not lead to a significant improvement in OS [
         <a href="#rid10">
          10
         </a>
         ]. The American trial showed no advantage for higher dose therapy in terms of either PFS or OS [
         <a href="#rid11">
          11
         </a>
         ]. Both trials indicated more side effects from higher-dose therapy.
        </p>
        <p>
         A meta-analysis of both trials came to the following conclusions [
         <a href="#rid38">
          38
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At a median follow-up of 45 months, compared with standard-dose
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         , a modest PFS advantage was seen with higher dose imatinib (hazard ratio [HR] for progression 0.89, 95% CI 0.79-1), but OS and best response (51 versus 54 percent) were similar.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence of a
         <em>
          KIT
         </em>
         exon 9 mutation was the only significant predictive factor for benefit from higher doses. Among the patients with an exon 9 mutation, compared with standard-dose
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         , higher dose imatinib was associated with improved PFS (HR 0.58, 95% CI 0.38-0.91) and overall response rates (47 versus 21 percent), but not OS. In the absence of such mutations, no difference in these outcomes was observed between the treatment arms.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h4">
          Pharmacokinetic variability
         </span>
         <span class="headingEndMark">
          —
         </span>
         Another possible explanation for the failure to demonstrate benefit from higher
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         doses in both trials is interpatient variability in pharmacokinetic exposure [
         <a href="#rid39">
          39,40
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 73 patients who were randomly assigned to 400 or 600 mg of
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         daily for advanced GIST, there was a 10-fold variance in trough levels with either dose (from 414 to 4182 ng/mL) [
         <a href="#rid39">
          39
         </a>
         ]. Clinical outcomes were correlated with trough levels at steady state. Trough values below 1100 ng/mL were associated with a significantly shorter time to tumor progression and a lower rate of clinical benefit as compared with higher trough levels.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Others have shown a significant correlation between low
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         trough levels and prior major gastrectomy, higher creatinine clearance, and high serum albumin levels [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Pharmacokinetic variability may also contribute to acquired drug resistance [
         <a href="#rid41">
          41
         </a>
         ]. In a small population-based pharmacokinetic study in patients with GIST,
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         clearance increased after long-term treatment (&gt;1 year), which reduced systemic exposure by 42 percent compared with the start of treatment [
         <a href="#rid42">
          42
         </a>
         ]. These findings were confirmed in a subsequent prospective population pharmacokinetic study of 50 patents with GIST being treated with imatinib [
         <a href="#rid43">
          43
         </a>
         ]. After 90 days of treatment, there was a significant decrease in imatinib exposure of 29 percent compared with baseline. However, there appeared to be no statistically significant effect of pharmacokinetic variability on PFS in the subset of patients treated with imatinib for advanced incurable disease.
        </p>
        <p>
         It is not yet clear whether increased
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         clearance is a significant factor in the amelioration of imatinib toxicity that occurs with time and/or has any impact on disease control; further work is required to ascertain the clinical implications of these observations.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Influence of mutations on response to therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         An assessment of mutation status is advised for patients with metastatic disease because clinical responses to
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         (and other TKIs) correlate with tumor genotype and influence treatment options and prognosis  (
         <a class="graphic graphic_algorithm graphicRef127116" href="/z/d/graphic/127116.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'KIT mutations'
         </a>
         below and
         <a class="local">
          'PDGFRA mutations'
         </a>
         below.)
        </p>
        <p>
         Approximately 10 percent of patients with GIST have primary resistance to
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         , defined as progression within the first six months of treatment. Many of these resistant tumors lack mutations in
         <em>
          KIT
         </em>
         or
         <em>
          PDGFRA
         </em>
         , or they harbor a
         <em>
          PDGFRA
         </em>
         D842V mutation. While we generally do not offer initial therapy with imatinib to these patients, the one notable exception is those with advanced spindle cell tumors of the GI tract. Imatinib may be effective in patients with these tumors, which appear histologically compatible with a diagnosis of GIST, even if they are immunohistochemically
         <em>
          KIT
         </em>
         negative, and these patients may be offered a trial of imatinib. (see
         <a class="medical medical_review" href="/z/d/html/7745.html" rel="external">
          "Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors", section on 'Other risk factors'
         </a>
         )
        </p>
        <p>
         The general approach to patients with a D842V mutation or a succinate dehydrogenase (SDH)-deficient GIST is discussed below. (See
         <a class="local">
          'Avapritinib for PDGFRA D842V mutant tumors'
         </a>
         below and
         <a class="local">
          'SDH-deficient tumors and those associated with NF1'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2706662688">
         <span class="h4">
          KIT mutations
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          Imatinib
         </a>
         is approved in the United States for the treatment of all
         <em>
          KIT
         </em>
         -expressing metastatic GISTs, regardless of mutation status. However, in our view and that of others [
         <a href="#rid44">
          44
         </a>
         ], assessment of mutation status is advised for most patients being treated for metastatic disease, given the predictive and prognostic information that is provided [
         <a href="#rid45">
          45
         </a>
         ]. Specific mutations in
         <em>
          KIT
         </em>
         (exon 11 versus exon 9) correlate with clinical response to imatinib  (
         <a class="graphic graphic_algorithm graphicRef127116" href="/z/d/graphic/127116.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
         For patients with a
         <em>
          KIT
         </em>
         exon 9 mutation, consensus-based guidelines from the NCCN suggest initiating therapy for unresectable or metastatic disease with a higher dose of
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         (800 mg daily) [
         <a href="#rid27">
          27
         </a>
         ]. Similarly, the European Society for Medical Oncology (ESMO) recommends mutation testing for all patients and considers this higher dose of imatinib to be a standard treatment for patients with a
         <em>
          KIT
         </em>
         exon 9 mutation [
         <a href="#rid44">
          44
         </a>
         ]. Although
         <em>
          KIT
         </em>
         exon 9 mutations are associated with an increased response rate to higher dose imatinib, OS is not improved. (See
         <a class="local">
          'Impact of dose'
         </a>
         above.)
        </p>
        <p>
         In the United States, for patients where the
         <em>
          KIT
         </em>
         mutational status is unknown, one treatment approach is to start with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         400 mg daily and increase the dose to 800 mg daily if there is no response. Initiation of second-line
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         is a reasonable alternative. Whether outcomes are better with early institution of sunitinib following progression on imatinib 400 mg daily is not known. (See
         <a class="local">
          'Sunitinib'
         </a>
         below.)
        </p>
        <p>
         Data are as follows [
         <a href="#rid46">
          46-50
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one study of 127 patients with GISTs receiving
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         , activating mutations in
         <em>
          KIT
         </em>
         and
         <em>
          PDGFRA
         </em>
         were found in approximately 88 and 5 percent, respectively [
         <a href="#rid46">
          46
         </a>
         ]. All
         <em>
          KIT
         </em>
         mutant isoforms were associated with a response to imatinib, while only a subset of
         <em>
          PDGFRA
         </em>
         mutants was imatinib sensitive. (See
         <a class="local">
          'PDGFRA mutations'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Among the patients with
         <em>
          KIT
         </em>
         mutations, those with an exon 11 mutation had a substantially greater likelihood of a partial response compared with patients with either an exon 9 mutation or no detectable mutation in either
         <em>
          KIT
         </em>
         or
         <em>
          PDGFRA
         </em>
         (84 versus 48 and 0 percent, respectively), and they had a longer time to treatment failure as well.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Data from two randomized trials (one from the United States Intergroup and another from the European Organisation for the Research and Treatment of Cancer [EORTC]), along with a meta-analysis of these two trials, suggest that higher daily doses of
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         may preferentially benefit those with exon 9 mutations [
         <a href="#rid38">
          38,49,51
         </a>
         ]. Data from the individual trials are discussed below, and data from the meta-analysis are reviewed above. (See
         <a class="local">
          'Impact of dose'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the United States Intergroup trial comparing two doses of
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         in 324 patients, patients whose tumors expressed an exon 11 mutant isoform were more likely to have an objective response to imatinib compared with those with an exon 9 isoform or those who had no kinase mutations (72 versus 44 and 45 percent, respectively) [
         <a href="#rid49">
          49
         </a>
         ]. Patients with an exon 11 mutation also had a significantly longer time to disease progression (25 versus 17 and 13 months, respectively) and median OS (median 60 versus 38 and 49 months, respectively).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the EORTC trial of 58 patients whose tumors expressed an exon 9 mutant KIT protein, an initial daily
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         dose of 800 mg resulted in a significantly superior PFS (HR for progression 0.39) compared with 400 mg/day [
         <a href="#rid51">
          51
         </a>
         ]. In contrast, the time to progression was not affected by the initial dose in patients with an exon
         <em>
          11 KIT
         </em>
         mutation or wild-ty
         <em>
          pe KIT
         </em>
         . There were no corresponding differences in OS between low-dose and high-dose initial therapy in patients with exon 9 mutations [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h4">
          PDGFRA mutations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Platelet-derived growth factor receptor alpha (
         <em>
          PDGFRA
         </em>
         ) mutations in exons 12, 14, and 18 occur in approximately 10 to 20 percent of patients with GIST, with a higher frequency among tumors that are
         <em>
          KIT
         </em>
         negative [
         <a href="#rid48">
          48
         </a>
         ]. However, not all
         <em>
          PDGFRA
         </em>
         activating mutations demonstrate the same biologic response to
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         . In particular, the D842V mutation in exon 18 confers relative primary resistance to imatinib  (
         <a class="graphic graphic_algorithm graphicRef127116" href="/z/d/graphic/127116.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid52">
          52-54
         </a>
         ].
        </p>
        <p>
         By contrast, other
         <em>
          PDGFRA
         </em>
         mutations appear to render GIST tumors sensitive to
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         [
         <a href="#rid46">
          46,48,55,56
         </a>
         ]. As an example, in one observational study of approximately 60 patients with
         <em>
          PDGFRA
         </em>
         mutant GIST, the response rate to imatinib was 0 percent among those with a D842V substitution versus 39 percent for those with non-D842V
         <em>
          PDGFRA
         </em>
         mutations [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
         Further details and available treatment options for patients with advanced and metastatic GISTs that harbor the
         <em>
          PDGFRA
         </em>
         D842V mutation are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7745.html" rel="external">
          "Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors", section on 'PDGFRA mutations'
         </a>
         and
         <a class="local">
          'Avapritinib for PDGFRA D842V mutant tumors'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Duration of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal duration of
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         therapy for responding patients with advanced/metastatic disease was addressed in a French trial that randomly assigned patients with advanced GIST and no disease progression after one year of imatinib to continuous treatment or interruption until disease progression [
         <a href="#rid57">
          57
         </a>
         ]. The study was stopped prematurely after only 58 patients had been randomized when it became evident that the risk of progression was significantly higher if therapy was interrupted, even in completely responding patients. In the initial report of the 32 patients who interrupted therapy, 26 progressed and needed retreatment, compared with only 8 of 26 in the continuous therapy arm (81 versus 31 percent). The corresponding median PFS durations were 18 versus 6 months. There were no significant differences between the groups with respect to survival, incidence of imatinib resistance, or quality of life. Drug reintroduction achieved tumor control in 24 of 26 of the patients whose therapy was interrupted.
        </p>
        <p>
         The study was subsequently amended to allow randomization after three or five years of therapy. In the final subset of 71 patients who remained free of progression after one (n = 32), three (n = 25), or five (n = 14) years of therapy and who were randomized to discontinue therapy, 51 patients had restarted
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         upon documentation of progressive disease [
         <a href="#rid58">
          58
         </a>
         ]. While 18 progressed only within known lesions, 33 (65 percent) had new lesions, with concurrent progression in the known lesions in 17. Only eight (42 percent) of the patients who had been in complete remission at randomization and 12 (52 percent) of the patients who had been in partial remission at randomization achieved a new complete or partial response, respectively, after reintroduction of imatinib.
        </p>
        <p>
         Thus, interruption of
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         results in rapid progression in most patients with advanced GIST, and it cannot be recommended unless there is significant toxicity or an intervening complication, such as the need to treat another diagnosis (eg, another cancer), in the same patient. Continuous therapy until disease progression (or lifelong if disease does not progress) is advised.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Side effects and their management
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          Imatinib
         </a>
         is generally well tolerated; most side effects are less than grade 2, and the majority of patients can continue treatment without interruption. In general, the side effect profile tends to improve with prolonged therapy [
         <a href="#rid59">
          59
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4508.html" rel="external">
          "Initial treatment of chronic myeloid leukemia in chronic phase", section on 'Imatinib'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4508.html" rel="external">
          "Initial treatment of chronic myeloid leukemia in chronic phase", section on 'Managing toxicity'
         </a>
         .)
        </p>
        <p>
         Minimal data have been published on managing the side effects of
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         [
         <a href="#rid45">
          45
         </a>
         ]. The most common side effects reported in GIST patients receiving imatinib are fluid retention, diarrhea, nausea, fatigue, muscle cramps, abdominal pain, and rash. These and other potentially more severe but less common side effects and proposed management strategies are summarized below.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fluid retention
         </strong>
         – Fluid retention with peripheral edema, and occasionally pleural effusion and ascites may be more common in older patients and in those with cardiac disease. Periorbital edema is more common and often does not respond to diuretics, but may improve with dietary salt restriction. It tends to be most prominent in the morning and decreases in intensity if the patient is upright during the day. (See
         <a class="medical medical_review" href="/z/d/html/96203.html" rel="external">
          "Ocular side effects of systemically administered chemotherapy", section on 'Imatinib'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients treated with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         in National Cancer Institute (NCI)-sponsored trials, the rate of grade 3/4 edema considered likely related to imatinib was 1.3 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Muscle cramps
         </strong>
         – Muscle cramps are perhaps the most bothersome long-term symptom associated with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         , most commonly affecting calves, feet, and hands. There is no definitive treatment, although anecdotally some patients have obtained benefit from treatment with calcium or magnesium supplements, or the use of
         <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">
          quinine
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nausea, vomiting, dyspepsia
         </strong>
         – Nausea and vomiting are generally not a problem when the drug is taken with food, which does not diminish absorption. Dyspepsia and GI upset may also be lessened by taking the drug with meals. Symptomatic treatment with antacids or proton pump inhibitors may be needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Abdominal discomfort and diarrhea
         </strong>
         – Flatulence and mild abdominal discomfort are common. Diarrhea is usually grade 1 to 2 but is occasionally more severe. Loose stools can usually be managed with
         <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">
          loperamide
         </a>
         or
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         sulfate/diphenoxylate hydrochloride.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rash
         </strong>
         – Skin rash is usually maculopapular and mild. It often resolves with continued treatment. Severe cases may respond to a short course of high-dose glucocorticoids [
         <a href="#rid60">
          60
         </a>
         ]. Some patients who flare on redosing may benefit from desensitization, starting with doses as low as 25 mg daily, using
         <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">
          cetirizine
         </a>
         as premedication. (See
         <a class="medical medical_review" href="/z/d/html/2088.html" rel="external">
          "Cutaneous adverse events of molecularly targeted therapy and other biologic agents used for cancer therapy", section on 'Maculopapular eruption'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hematologic toxicity
         </strong>
         – Mild anemia is common with chronic use or higher doses [
         <a href="#rid61">
          61
         </a>
         ]. Treatment with erythropoietin may benefit the occasional patient with more severe anemia. Macrocytosis, with elevation of the mean corpuscular volume, is observed frequently; the mechanism is unknown.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Neutropenia is rare. Patients may safely continue the drug as long as the absolute neutrophil count is ≥1000 cells/microL. Withholding the drug usually leads to resolution of neutropenia, often within days. Reinitiation of the same drug dose is often accomplished without reoccurrence; dose reduction may be needed if the patient continues to experience significant neutropenia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypophosphatemia
         </strong>
         – Hypophosphatemia is reported, especially with higher doses [
         <a href="#rid62">
          62,63
         </a>
         ]. Routine monitoring of phosphate levels has been suggested by the manufacturer [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gynecomastia
         </strong>
         – Gynecomastia was reported in 7 of 38 men receiving
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         for chronic myeloid leukemia (CML) and associated with reduced levels of free testosterone. Gynecomastia is not yet reported in men receiving imatinib for GIST.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lung and liver toxicity
         </strong>
         – Lung toxicity and elevation of liver function tests (LFTs) have only occasionally been reported. Fatal hepatotoxicity was noted in a patient in blast crisis who was taking large doses of
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         concurrently, and it is recommended that acetaminophen use be avoided, if possible. At least some data suggest that concomitant administration of
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         and corticosteroids may permit continued imatinib treatment in patients who develop LFT abnormalities [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiac toxicity
         </strong>
         – The issue of cardiac toxicity is unresolved. In 2006, there was a report of severe heart failure developing in 10 individuals receiving
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         , although the disease for which treatment was being given was not specified [
         <a href="#rid66">
          66
         </a>
         ]. Subsequent experience suggests that among patients receiving imatinib for CML, there is a risk for heart failure, but the risk is fairly low and probably limited to those with pre-existing heart disease. (See
         <a class="medical medical_review" href="/z/d/html/4508.html" rel="external">
          "Initial treatment of chronic myeloid leukemia in chronic phase", section on 'Imatinib'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Whether
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         causes cardiac toxicity in patients treated for GIST is unclear; the following information on this issue is available:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A report from the EORTC study of
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         400 versus 800 mg noted no excess of clinical cardiac events in the study population who were treated for a median of 24 months [
         <a href="#rid67">
          67
         </a>
         ]. (See
         <a class="local">
          'Impact of dose'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A retrospective review of the MD Anderson experience of 219 patients enrolled in clinical trials of
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         for GIST over a six-year period identified potential cardiac adverse events in 18 (8 percent) [
         <a href="#rid68">
          68
         </a>
         ]. The adverse events included dyspnea, chest pain, edema, pleural effusion, ascites, cardiac ischemia and arrhythmia. Thirteen had risk factors for coronary artery disease or established heart disease. None of the patients had evidence of pulmonary vascular congestion on chest radiography. Of the eight patients who underwent echocardiography or radionuclide ventriculography, only one had a left ventricular ejection fraction &lt;50 percent. All patients were able to continue imatinib with dose adjustment and toxicity-specific management.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In the landmark phase III placebo-controlled adjuvant
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         trial, there was no excess of cardiotoxicity in the group that received one year of postoperative imatinib. (See
         <a class="medical medical_review" href="/z/d/html/7730.html" rel="external">
          "Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors", section on 'Phase III trials'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Until further information becomes available, the following actions would be prudent:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         As part of the informed consent process, patients taking
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         should be notified that heart failure may be a rare but potentially serious adverse event.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients currently taking
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         should be monitored for signs and symptoms of left ventricular systolic dysfunction.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Heart failure should be considered in the differential diagnosis of any patient experiencing peripheral edema while receiving this agent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          GI bleeding
         </strong>
         – Patients with large bulky tumors have a 5 percent risk of tumor hemorrhage not associated with thrombocytopenia. These patients should be closely monitored for a drop in hemoglobin in the first four to eight weeks of therapy [
         <a href="#rid45">
          45
         </a>
         ]. If the hemoglobin level acutely decreases ≥2 g/dL,
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         should be temporarily withheld until blood counts have stabilized, with transfusion if needed. Emergent surgical intervention may be needed if bleeding does not resolve. However, emergency surgery is uncommonly needed. It was required in three of 232 patients in one report (1.3 percent) [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If life-threatening side effects, such as GI bleeding, develop that cannot be managed with maximal supportive care, a switch to
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         should be considered. (See
         <a class="local">
          'Treatment of disease refractory to imatinib'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ocular toxicity
         </strong>
         – In addition to periorbital edema,
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         is associated with epiphora (excess tearing), spontaneous conjunctival/subconjunctival hemorrhage, and rare instances of retinal hemorrhage and optic neuritis. (See
         <a class="medical medical_review" href="/z/d/html/96203.html" rel="external">
          "Ocular side effects of systemically administered chemotherapy", section on 'Imatinib'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4252371097">
         <span class="h2">
          Exceptions
         </span>
        </p>
        <p class="headingAnchor" id="H1067379801">
         <span class="h3">
          Avapritinib for PDGFRA D842V mutant tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with symptomatic and/or rapidly progressive disease harboring a
         <strong>
          platelet-derived growth factor receptor alpha (
         </strong>
         <strong>
          <em>
           PDGFRA
          </em>
         </strong>
         <strong>
          )
         </strong>
         <strong>
          <em>
          </em>
         </strong>
         <strong>
          exon 18 D842V
         </strong>
         <strong>
          <em>
          </em>
         </strong>
         <strong>
          mutation
         </strong>
         , we recommend
         <a class="drug drug_general" data-topicid="126556" href="/z/d/drug information/126556.html" rel="external">
          avapritinib
         </a>
         over either
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         or observation in the setting of initial therapy. These tumors often demonstrate primary resistance to imatinib, whereas the response rate with avapritinib is high (approximately 90 percent)  (
         <a class="graphic graphic_algorithm graphicRef127116" href="/z/d/graphic/127116.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
         For those with the
         <em>
          PDGFRA
         </em>
         D842V mutation who exhibit asymptomatic and/or indolent disease, a period of observation is preferable to immediate therapy with
         <a class="drug drug_general" data-topicid="126556" href="/z/d/drug information/126556.html" rel="external">
          avapritinib
         </a>
         in order to avoid treatment-related toxicities, such as potential cognitive impairment. In these patients, avapritinib may be initiated at the onset of symptomatic and/or rapidly progressive disease.
         <a class="drug drug_general" data-topicid="128227" href="/z/d/drug information/128227.html" rel="external">
          Ripretinib
         </a>
         , another agent targeting the
         <em>
          PDGFRA
         </em>
         D842V mutation, is approved for patients who have progressed on multiple TKIs. (See
         <a class="local">
          'Ripretinib'
         </a>
         below.)
        </p>
        <p>
         This is in contrast to the approach for patients with GISTs harboring a
         <strong>
          <em>
           PDGFRA
          </em>
         </strong>
         <strong>
          exon 18 mutation other than D842V
         </strong>
         . Although
         <a class="drug drug_general" data-topicid="126556" href="/z/d/drug information/126556.html" rel="external">
          avapritinib
         </a>
         is active for such patients, other agents (including
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         , and
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         ) also are effective, and avapritinib is typically reserved for use after progression on these therapies  (
         <a class="graphic graphic_algorithm graphicRef127116" href="/z/d/graphic/127116.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'PDGFRA mutations'
         </a>
         above and
         <a class="local">
          'Treatment of disease refractory to imatinib, sunitinib, and regorafenib'
         </a>
         below.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="126556" href="/z/d/drug information/126556.html" rel="external">
          Avapritinib
         </a>
         is administered at 300 mg daily until disease progression, intolerance, or unacceptable toxicity occurs. Avapritinib is associated with central nervous system toxicities, including cognitive impairment; mood, speech, or sleep disorders; dizziness; hallucinations; and intracranial hemorrhage. Patients must be closely monitored for these central nervous system toxicities, with appropriate dose reductions or permanent discontinuation of avapritinib as clinically indicated [
         <a href="#rid70">
          70
         </a>
         ]. Of note, it has been our experience that some cognitive impairment from avapritinib may persist despite dose modification or discontinuation of treatment, and further follow-up is needed to determine the duration and potential reversal of symptoms. (See
         <a class="medical medical_review" href="/z/d/html/2825.html" rel="external">
          "Neurologic complications of cancer treatment with molecularly targeted and biologic agents", section on 'Dasatinib, imatinib, and avapritinib'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="126556" href="/z/d/drug information/126556.html" rel="external">
          Avapritinib
         </a>
         is also teratogenic; therefore, females of reproductive potential or males with female partners of reproductive potential should use effective contraception while on therapy as well as for six weeks after the final dose is administered.
        </p>
        <p>
         The efficacy of
         <a class="drug drug_general" data-topicid="126556" href="/z/d/drug information/126556.html" rel="external">
          avapritinib
         </a>
         was evaluated in a single-arm, open-label, phase I clinical trial (NAVIGATOR) [
         <a href="#rid71">
          71,72
         </a>
         ]. In this study, a cohort of 56 patients with GIST containing the
         <em>
          PDGFRA
         </em>
         exon 18 D842V mutation received avapritinib at 300 or 400 mg daily. Patients with a D842V mutation were not required to have received prior systemic therapy. After a median follow-up of approximately 28 months, overall responses for those with the D842V mutation were seen in 51 patients (91 percent), including seven complete responders (13 percent) and 44 partial responders (79 percent). One-year PFS and three-year OS rates were 83 and 61 percent, respectively.
        </p>
        <p>
         Grade ≥3 toxicities included anemia (28 percent), hyperbilirubinemia (9 percent), fatigue (9 percent), abdominal pain (6 percent), diarrhea (5 percent), cognitive impairment (5 percent), edema (2 percent), and pleural effusion (2 percent) [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
         Based on these phase I results, the US Food and Drug Administration (FDA) granted approval to
         <a class="drug drug_general" data-topicid="126556" href="/z/d/drug information/126556.html" rel="external">
          avapritinib
         </a>
         for patients with unresectable or metastatic GISTs with a
         <em>
          PDGFRA
         </em>
         exon 18 mutation [
         <a href="#rid73">
          73
         </a>
         ]. Further randomized trials comparing avapritinib with other standard therapies are needed to confirm these results.
        </p>
        <p>
         Limited data suggest that
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         and the investigational agent crenolanib (a TKI with specificity for
         <em>
          PDGFRA
         </em>
         , platelet-derived growth factor beta [
         <em>
          PDGFRB
         </em>
         ], and fms-like tyrosine kinase 3 [
         <em>
          FLT3
         </em>
         ]) may also be active against tumors with a
         <em>
          PDGFRA
         </em>
         D842V mutation [
         <a href="#rid74">
          74-76
         </a>
         ]. These results require further investigation. (See
         <a class="local">
          'Investigational therapies'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1768266875">
         <span class="h3">
          SDH-deficient tumors and those associated with NF1
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many tumors that lack mutations in
         <em>
          KIT
         </em>
         and
         <em>
          PDGFRA
         </em>
         (so-called wild-type tumors) are deficient in expression of one or more subunits of the genes that encode the proteins that form the succinate dehydrogenase (SDH) protein complex. SDH-deficient tumors have a high rate of primary resistance to various TKIs but a comparatively indolent course [
         <a href="#rid77">
          77,78
         </a>
         ]. The best way to treat these patients is not established. Although they are refractory to
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         , they may have some responsiveness to
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         or
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         . Referral to an expert center is preferred. These patients are also good candidates for clinical trials  (
         <a class="graphic graphic_algorithm graphicRef127116" href="/z/d/graphic/127116.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Sunitinib'
         </a>
         below and
         <a class="local">
          'Regorafenib'
         </a>
         below.)
        </p>
        <p>
         As an example, in one report of 95 patients with
         <em>
          KIT
         </em>
         /
         <em>
          PDGFRA
         </em>
         wild-type GIST (84 of which were SDH deficient), only 1 of 49 patients treated with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         had a partial response, and there were only four objective responses to
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         (one complete, three partial) [
         <a href="#rid77">
          77
         </a>
         ]. Of the 63 patients with
         <em>
          SDH
         </em>
         mutant GIST followed for a median of six (range 1 to 44) years, only three had died (from 8 to 24 years after initial diagnosis); in contrast, 3 of 11 (27 percent) patients with SDH-competent wild-type GIST had died of progressive disease with a median follow-up of eight years (range 2 to 17). (See
         <a class="medical medical_review" href="/z/d/html/7745.html" rel="external">
          "Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors", section on 'KIT/PDGFRA wild-type GISTs'
         </a>
         .)
        </p>
        <p>
         Patients with neurofibromatosis type 1 (NF1), an inherited cancer predisposition syndrome that is caused by a mutation in the
         <em>
          NF1
         </em>
         gene that encodes neurofibromin, have an increased risk of GIST. GISTs that arise in these patients may be
         <em>
          KIT
         </em>
         expressing, but they lack mutations in
         <em>
          KIT
         </em>
         and
         <em>
          PDGFRA
         </em>
         . These tumors rarely respond to
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         [
         <a href="#rid79">
          79
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7745.html" rel="external">
          "Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors", section on 'Pathogenesis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3533821519">
         <span class="h1">
          ROLE OF SURGERY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The role of surgery in patients with metastatic disease is addressed separately. (See
         <a class="medical medical_review" href="/z/d/html/7727.html" rel="external">
          "Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract", section on 'Metastatic GIST with potentially resectable disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          TREATMENT OF DISEASE REFRACTORY TO IMATINIB
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dose escalation is an option for patients with primary as well as secondary (late) resistance to standard doses of
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         . Patients who are intolerant of imatinib are better served by switching to an alternative tyrosine kinase inhibitor (TKI),
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         .
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Dose escalation of imatinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dose escalation may be considered in patients started on
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         400 mg daily who, after careful review of radiologic studies, are judged to have clear evidence of disease progression. The efficacy of this approach was shown in follow-up reports from both the American and European randomized dose-finding studies described above [
         <a href="#rid11">
          11,80
         </a>
         ] (see
         <a class="local">
          'Impact of dose'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the European study described above [
         <a href="#rid10">
          10
         </a>
         ], 247 of the 473 patients randomly assigned to low-dose therapy progressed, and 133 were crossed over to higher dose therapy (400 mg twice daily) [
         <a href="#rid80">
          80
         </a>
         ]. There were three confirmed partial responses, and 36 patients had prolonged periods of stable disease. Anemia and fatigue increased on the higher dose, but 18 percent were still alive and progression-free at one year.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Similar results were noted in the American trial [
         <a href="#rid11">
          11
         </a>
         ]. Of the 164 patients progressing on low-dose therapy, 133 crossed over to 800 mg daily. Following crossover, 31 percent of assessable patients (n = 117) achieved either an objective response (n = 3) or stable disease (n = 33). The median durations of progression-free survival (PFS) and overall survival (OS) after crossover were 5 and 19 months, respectively.
        </p>
        <p>
        </p>
        <p>
         Increasing the dose is unlikely to benefit patients who progress rapidly (within two months) after starting therapy.
        </p>
        <p class="headingAnchor" id="H25772305">
         <span class="h2">
          Alternative therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Emerging data suggest that selection of clones with secondary
         <em>
          KIT
         </em>
         mutations that cluster in the ATP-binding pocket and the activation loop of the kinase domain is the most common mechanism of secondary
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         resistance [
         <a href="#rid81">
          81-87
         </a>
         ]. Possible methods of overcoming imatinib resistance include resection of metastases to remove resistant clones, the use of more-powerful selective TKIs, multitargeted inhibitors, or combination therapies utilizing selective inhibitors of the tyrosine kinase receptor itself coupled with selective inhibitors of downstream pathways. In vitro studies suggest that the choice of TKI for imatinib-refractory GIST might depend, at least in part, on the specific mutation responsible for the acquisition of resistance [
         <a href="#rid87">
          87,88
         </a>
         ]. However, these data require validation in human subjects before they can be applied to clinical practice.
        </p>
        <p class="headingAnchor" id="H3792530419">
         <span class="h3">
          Metastasectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surgical resection may be considered in selected patients. In general, resection appears to benefit responding patients (ie, those who have a partial response, stable disease, or focal progression while receiving
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         , and possibly those with isolated sites of progression) but has little to offer those who experience generalized or multifocal disease progression. The goal of metastasectomy is to halt disease progression by eliminating resistant clones. The appropriate timing of surgical intervention is not established. This subject is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7727.html" rel="external">
          "Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract", section on 'Metastatic GIST with potentially resectable disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h3">
          Sunitinib
         </span>
        </p>
        <p class="headingAnchor" id="H3959049467">
         <span class="h4">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The multitargeted TKI
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         is active in imatinib-refractory or intolerant patients [
         <a href="#rid89">
          89-95
         </a>
         ]. An international phase III trial of sunitinib versus placebo in 312 patients with refractory disease definitively established the role of sunitinib in this setting [
         <a href="#rid92">
          92
         </a>
         ]. Patients demonstrating progression (by Response Evaluation Criteria In Solid Tumors [RECIST] version 1.0) while on placebo crossed over to the active treatment arm. In the latest update, at a median follow-up of 42 months, despite a low objective response rate in the sunitinib group (7 percent partial response), median time to tumor progression, the primary endpoint, was fourfold higher as compared with the placebo group (27 versus 6 weeks) [
         <a href="#rid94">
          94
         </a>
         ]. Although survival was significantly better with sunitinib in the initial report [
         <a href="#rid92">
          92
         </a>
         ], over time, as expected, OS converged (median 73 versus 65 weeks) [
         <a href="#rid94">
          94
         </a>
         ]. The median number of weeks on treatment was 22.
        </p>
        <p>
         As with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         , the clinical activity of
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         is significantly influenced by the specific mutation type [
         <a href="#rid91">
          91,96
         </a>
         ]. This was shown in a phase I/II trial performed in 97 patients with metastatic, imatinib-refractory or intolerant GISTs [
         <a href="#rid91">
          91
         </a>
         ]. Clinical benefit (partial response or stable disease for longer than six months) was significantly higher for those with a primary
         <em>
          KIT
         </em>
         9 exon (58 percent) or wild-type
         <em>
          KIT
         </em>
         /platelet-derived growth factor receptor alpha (
         <em>
          PDGFRA
         </em>
         ) mutation (56 percent) than for those with a
         <em>
          KIT
         </em>
         exon 11 mutation (34 percent). The same pattern was seen for PFS and OS. Following progression on imatinib, patients with
         <em>
          KIT
         </em>
         exon 9 mutation or a
         <em>
          PDGFRA
         </em>
         mutation had a median time to progression of 19 months, while for those with exon 11 mutations, it was only five months. There was also a correlation between secondary mutations and response to sunitinib. Both PFS and OS were significantly longer for patients with secondary
         <em>
          KIT
         </em>
         exon 13 or 14 mutations than for those with exon 17 or 18 mutations (7.8 versus 2.3 months).
        </p>
        <p>
         As with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         , PET scans can permit an earlier assessment of response than conventional CT scans [
         <a href="#rid90">
          90,97
         </a>
         ] but are rarely used outside of the context of a clinical trial, except in patients who cannot tolerate intravenous contrast or magnetic resonance imaging (MRI) as other means of evaluating metastatic GISTs radiologically. (See
         <a class="local">
          'Assessing response to therapy'
         </a>
         above.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          Sunitinib
         </a>
         is approved in the United States for the treatment of imatinib-refractory or intolerant advanced GISTs. The approved dose is 50 mg daily for four of every six weeks. However, continuous daily dosing (37.5 mg daily) appears similarly safe and effective [
         <a href="#rid98">
          98
         </a>
         ].
        </p>
        <p>
         Resistance to
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         shares similar pathogenetic mechanisms to those identified in
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         failure, with acquisition of secondary mutations after an extended initial response to the drug [
         <a href="#rid99">
          99
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h4">
          Side effects and management
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          Sunitinib
         </a>
         can cause fatigue, nausea, vomiting, anemia, neutropenia, diarrhea, abdominal pain, mucositis, anorexia, hypothyroidism, and discoloration of skin and hair. Other less common toxicities include bleeding, fever, hypertension, hand-foot skin reaction, myelosuppression, proteinuria and other forms of renal toxicity, elevation in serum amylase and lipase, and reduced left ventricular ejection fraction/clinical heart failure. Most sunitinib-related toxicities can be managed symptomatically or with temporary withdrawal or dose reduction. In severe cases, the drug may need to be discontinued.
        </p>
        <p>
         The following represents a brief synopsis of the most common toxicities seen with
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         :
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Renal toxicity
         </strong>
         – Small molecule TKIs that target the vascular endothelial growth factor receptors (VEGFR) are associated with proteinuria, which is rarely nephrotic range (&gt;3.5 g/24 hours) and, even more rarely, associated with the nephrotic syndrome. Hypertension frequently accompanies proteinuria. The factors associated with both the occurrence and the severity of proteinuria in patients treated with
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         are incompletely characterized.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There are no published guidelines for managing albuminuria during
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         treatment; however, good clinical practice dictates obtaining a baseline urinalysis with periodic assessment of proteinuria. Treatment interruption is appropriate management for patients who develop moderate to severe proteinuria (≥3 g/24 hours). (See
         <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">
          "Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Kidney toxicity'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hematologic toxicity
         </strong>
         –
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          Sunitinib
         </a>
         may cause myelosuppression. Sunitinib should be held if the absolute neutrophil count is ≤1000 cells/mm
         <sup>
          3
         </sup>
         . Recurrent episodes of grade 3 or 4 neutropenia or thrombocytopenia should prompt dose reduction to 37.5 or 25 mg daily [
         <a href="#rid45">
          45
         </a>
         ]. Anemia, if acute, should prompt interruption of sunitinib and a search for a source of bleeding or evidence for hemolysis. (See
         <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">
          "Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Myelosuppression'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Rarely,
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         has been associated with a thrombotic microangiopathy (TMA), which may include a thrombotic thrombocytopenic purpura (TTP) or hemolytic uremic syndrome (HUS)-type picture with microangiopathic hemolysis and renal failure. Hypertension is present in most cases. Withdrawal of sunitinib is crucial because this toxicity is potentially life-threatening. Other aspects of management are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/98720.html" rel="external">
          "Drug-induced thrombotic microangiopathy (DITMA)", section on 'Management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypothyroidism
         </strong>
         – Hypothyroidism is a frequent complication of prolonged
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         therapy. In one series, 15 of 42 euthyroid patients with intact thyroid glands (36 percent) became hypothyroid (as defined as a persistently elevated level of thyroid stimulating hormone [TSH]) while receiving sunitinib for advanced GIST [
         <a href="#rid100">
          100
         </a>
         ]. The risk increased with longer duration of therapy (18, 29, and 90 percent in patients treated for 36, 52, and 96 weeks, respectively). The mean time to development of hypothyroidism was 50 weeks. Because of the high prevalence of hypothyroidism, regular surveillance of TSH levels is warranted during sunitinib therapy. We and others [
         <a href="#rid101">
          101
         </a>
         ] suggest that thyroid function be evaluated at baseline and monitored at monthly intervals. (See
         <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">
          "Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Thyroid dysfunction'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7893.html" rel="external">
          "Diagnosis of and screening for hypothyroidism in nonpregnant adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7855.html" rel="external">
          "Treatment of primary hypothyroidism in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Another potential mechanism for hypothyroidism that should be considered in patients being treated with antiangiogenic TKIs for advanced GIST is consumptive hypothyroidism due to excessive degradation of thyroid hormone. However, this appears to be caused by overexpression of the thyroid hormone inactivating enzyme type 3 iodothyronine deiodinase (D3) within large GISTs and is not a drug-related adverse effect. This subject is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7886.html" rel="external">
          "Disorders that cause hypothyroidism", section on 'Consumptive hypothyroidism'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7745.html" rel="external">
          "Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors", section on 'Clinical presentation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypertension and cardiac toxicity
         </strong>
         – Patients should be closely monitored for hypertension and evidence of cardiac dysfunction while receiving
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/14250.html" rel="external">
          "Cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Hypertension'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14250.html" rel="external">
          "Cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Left ventricular dysfunction and myocardial ischemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The frequency of these events in patients treated with
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         for GIST can be illustrated by the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a study of 75 patients treated with
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         for imatinib-resistant GISTs, 47 percent developed hypertension (defined as a blood pressure &gt;150/100 mmHg) during therapy [
         <a href="#rid102">
          102
         </a>
         ]. In addition, 10 of 36 patients (28 percent) who were serially assessed had a ≥10 percent decline in left ventricular ejection fraction (LVEF) during therapy, and clinical heart failure developed in six (8 percent). Heart failure and decreased LVEF generally resolved with medical management and withdrawal of sunitinib.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Somewhat lower rates of treatment-related hypertension (20 percent, any grade), decreased ejection fraction (8 percent), and left ventricular dysfunction (2 percent) were reported in the longitudinal report of the phase III trial of
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         versus placebo discussed above [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gastrointestinal (GI) bleeding and/or bowel perforation
         </strong>
         – Patients who are treated with
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         for advanced GIST can develop GI bleeding or a bowel perforation. In one series, emergency surgery for hemorrhage, tumor perforation, or abscess was required in 4 of 43 patients during second-line therapy with sunitinib [
         <a href="#rid69">
          69
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">
          "Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Bleeding'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">
          "Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Intestinal perforation/fistula formation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Potential for delayed wound healing
         </strong>
         – Impaired wound healing (and reopening of previously healed wounds) has been observed following treatment with all TKIs that target VEGF, including
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         . However, at least some data support the view that wound healing complications are not more common after extensive GIST resections in patients on sunitinib as compared with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         [
         <a href="#rid103">
          103
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">
          "Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Delayed wound healing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Because of the potential for wound healing problems, many clinicians suggest interruption of therapy for at least one week before surgery, and not reinitiating until adequate wound healing has occurred. However, given that these tumors can progress quite rapidly off therapy, it is our practice to continue
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         until three to four days prior to surgery and to resume the drug at the first postoperative visit. (See
         <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">
          "Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Delayed wound healing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2021960598">
         <span class="h3">
          Is there a role for ripretinib?
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do not offer
         <a class="drug drug_general" data-topicid="128227" href="/z/d/drug information/128227.html" rel="external">
          ripretinib
         </a>
         to patients with disease refractory to
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         . In a randomized phase III trial, ripretinib was better tolerated but did not improve PFS over
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         [
         <a href="#rid104">
          104
         </a>
         ]. Ripretinib is indicated for disease refractory to multiple TKIs (imatinib, sunitinib, and
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         ). (See
         <a class="local">
          'Ripretinib'
         </a>
         below.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="128227" href="/z/d/drug information/128227.html" rel="external">
          Ripretinib
         </a>
         was evaluated in a randomized phase III trial (INTRIGUE) of 453 patients with advanced GISTs who experienced disease progression on or were intolerant to
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         [
         <a href="#rid104">
          104
         </a>
         ]. In this study, ripretinib resulted in similar PFS compared with
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         in those with a
         <em>
          KIT
         </em>
         exon 11 mutation (median 8.3 versus 7 months, HR 0.88, 95% CI 0.66-1.16) and among the entire study population (median PFS 8 versus 8.3 months, HR 1.05, 95% CI 0.82-1.33). Compared with sunitinib, ripretinib had higher objective response rates (24 versus 15 percent) and lower grade ≥3 treatment-related toxicities (27 versus 55 percent). In a subgroup analysis of patients with disease harboring a
         <em>
          KIT
         </em>
         exon 11 mutation, ripretinib was more effective in tumors with secondary resistance mutations in
         <em>
          KIT
         </em>
         exons 17 or 18 [
         <a href="#rid105">
          105
         </a>
         ]. In contrast, sunitinib was more effective in those with secondary resistance mutations in
         <em>
          KIT
         </em>
         exons 13 or 14.
        </p>
        <p class="headingAnchor" id="H1305730389">
         <span class="h1">
          TREATMENT OF DISEASE REFRACTORY TO IMATINIB AND SUNITINIB
         </span>
        </p>
        <p class="headingAnchor" id="H355376706">
         <span class="h2">
          Regorafenib
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with imatinib- and sunitinib-refractory GIST, we recommend
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         rather other tyrosine kinase inhibitors (TKIs), as this approach improved PFS in a randomized phase III trial [
         <a href="#rid106">
          106
         </a>
         ]. Additionally, regorafenib may confer greater benefit among such patients harboring mutations in
         <em>
          KIT
         </em>
         exon 11 or succinate dehydrogenase (SDH) [
         <a href="#rid107">
          107
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          Regorafenib
         </a>
         is an orally active TKI that is structurally similar to
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         and targets a variety of kinases including KIT, platelet-derived growth factor receptor (PDGFR), and VEGFR.
        </p>
        <p>
         Based on data from phase II trials [
         <a href="#rid107">
          107,108
         </a>
         ],
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         was evaluated in a double-blind, placebo-controlled phase III trial (GRID) conducted in 199 patients with metastatic or unresectable GIST refractory to or intolerant of
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         . Patients were randomly assigned to best supportive care plus either regorafenib (160 mg once daily for three of every four weeks) or placebo [
         <a href="#rid106">
          106
         </a>
         ]. Compared with placebo, regorafenib improved progression-free survival (PFS; 4.8 versus 0.9 months, HR 0.27, 95% CI 0.19-0.39) but not overall survival (OS; HR 0.77, 95% CI 0.42-1.41). The lack of OS benefit was likely due to the crossover design, as a majority (85 percent) of patients in the placebo group received regorafenib upon disease progression.
        </p>
        <p>
         Grade ≥3 toxicities for
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         included hypertension (23 percent), hand-foot skin reaction (20 percent), and diarrhea (5 percent). Treatment-related toxicity with regorafenib is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">
          "Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14250.html" rel="external">
          "Cardiovascular toxicities of molecularly targeted antiangiogenic agents"
         </a>
         .)
        </p>
        <p>
         Based on these data, the US Food and Drug Administration (FDA) approved
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         for treatment of metastatic or unresectable GIST no longer responsive to
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         and
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         .
        </p>
        <p class="headingAnchor" id="H1271658833">
         <span class="h1">
          TREATMENT OF DISEASE REFRACTORY TO IMATINIB, SUNITINIB, AND REGORAFENIB
         </span>
        </p>
        <p class="headingAnchor" id="H930857255">
         <span class="h2">
          Ripretinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with GIST (irrespective of D842V mutation status) who have progressed on or are intolerant of three or more tyrosine kinase inhibitors (TKIs), including
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         , we suggest
         <a class="drug drug_general" data-topicid="128227" href="/z/d/drug information/128227.html" rel="external">
          ripretinib
         </a>
         over other available TKIs, as this agent improved survival and was well tolerated in a placebo-controlled randomized trial [
         <a href="#rid109">
          109
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="128227" href="/z/d/drug information/128227.html" rel="external">
          Ripretinib
         </a>
         is administered at an initial dose of 150 mg daily until disease progression, intolerance, or unacceptable toxicity occurs [
         <a href="#rid110">
          110
         </a>
         ]. For patients who progress on ripretinib 150 mg daily, the dose can be escalated to 150 mg twice a day [
         <a href="#rid111">
          111,112
         </a>
         ].
        </p>
        <p>
         Management considerations specific to use of
         <a class="drug drug_general" data-topicid="128227" href="/z/d/drug information/128227.html" rel="external">
          ripretinib
         </a>
         are as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The use of concomitant
         <strong>
          strong
         </strong>
         and
         <strong>
          moderate
         </strong>
         CYP3A inducers  (
         <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">
          table 3
         </a>
         ) with
         <a class="drug drug_general" data-topicid="128227" href="/z/d/drug information/128227.html" rel="external">
          ripretinib
         </a>
         should be avoided.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If the concomitant use of
         <strong>
          moderate
         </strong>
         CYP3A inducers cannot be avoided, the
         <a class="drug drug_general" data-topicid="128227" href="/z/d/drug information/128227.html" rel="external">
          ripretinib
         </a>
         dose should be increased to 150 mg twice daily during the co-administration period, with monitoring for efficacy and toxicity. Ripretinib can be resumed at 150 mg daily two weeks after the
         <strong>
          moderate
         </strong>
         CYP3A inducer is stopped [
         <a href="#rid113">
          113
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3568.html" rel="external">
          "Drugs and the liver: Metabolism and mechanisms of injury"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We obtain a baseline echocardiogram or MUGA scan prior to initiation of therapy and as clinically indicated afterwards;
         <a class="drug drug_general" data-topicid="128227" href="/z/d/drug information/128227.html" rel="external">
          ripretinib
         </a>
         should be discontinued in those who develop grade ≥3 left ventricular diastolic dysfunction on treatment. (See
         <a class="medical medical_review" href="/z/d/html/14250.html" rel="external">
          "Cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Specific VEGFR tyrosine kinase inhibitors'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2812.html" rel="external">
          "Cardiotoxicity of cancer chemotherapy agents other than anthracyclines, HER2-targeted agents, and fluoropyrimidines", section on 'Ripretinib'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients should receive regular dermatologic evaluation, as
         <a class="drug drug_general" data-topicid="128227" href="/z/d/drug information/128227.html" rel="external">
          ripretinib
         </a>
         is associated with the development of primary cutaneous malignancies (such as squamous cell carcinoma and melanoma), alopecia, and hand-foot skin reaction syndrome. (See
         <a class="medical medical_review" href="/z/d/html/103060.html" rel="external">
          "Hand-foot skin reaction induced by multitargeted tyrosine kinase inhibitors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients of reproductive potential and their partners should use effective contraception during therapy and for at least one week after treatment completion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="128227" href="/z/d/drug information/128227.html" rel="external">
          Ripretinib
         </a>
         should be held for at least one week prior to elective surgeries and at least two weeks after major surgery to reduce the risk of wound healing complications.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The approach to monitoring and managing hypertension in patients treated with
         <a class="drug drug_general" data-topicid="128227" href="/z/d/drug information/128227.html" rel="external">
          ripretinib
         </a>
         is similar to that used with antiangiogenic agents and is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14250.html" rel="external">
          "Cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Hypertension'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="128227" href="/z/d/drug information/128227.html" rel="external">
          Ripretinib
         </a>
         , a "switch control" inhibitor, targets multiple molecular alterations present in GIST, including several
         <em>
          KIT
         </em>
         mutations (exon 9, 11, 13, 14, 17, and 18), by stabilizing the KIT molecule into an inactive form. Ripretinib also targets
         <em>
          PDGFRA
         </em>
         mutations in exon 18, including the D842V resistance mutation, and the D816V secondary resistance mutation in exon 17, which is also present in most patients with systemic mastocytosis. (See
         <a class="medical medical_review" href="/z/d/html/4787.html" rel="external">
          "Advanced systemic mastocytosis: Management and prognosis"
         </a>
         .)
        </p>
        <p>
         In a phase III trial (INVICTUS), 129 patients with advanced GIST either refractory to or intolerant of
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         , and
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         were randomly assigned to
         <a class="drug drug_general" data-topicid="128227" href="/z/d/drug information/128227.html" rel="external">
          ripretinib
         </a>
         or placebo [
         <a href="#rid109">
          109
         </a>
         ]. At median follow-up of 6 months, ripretinib improved median overall survival (OS; 15 versus 6 months, hazard ratio [HR] 0.36, 95% CI 0.20-0.62) relative to placebo. Ripretinib also improved progression-free survival (PFS; six versus one month; six-month PFS 51 versus 3 percent, HR 0.15, 95% CI 0.09-0.25) in all patients regardless of mutation status [
         <a href="#rid109">
          109
         </a>
         ] and in each subgroup with specific
         <em>
          KIT
         </em>
         mutations (exons 11, 9, 13, and 17) relative to placebo [
         <a href="#rid114">
          114
         </a>
         ]. Objective response rates were also higher for ripretinib compared with placebo (9 versus 0 percent). Ripretinib was well tolerated, as the number of patients who discontinued or interrupted treatment due to adverse events was similar between ripretinib and placebo. Grade ≥3 treatment-related toxicities included anemia (9 percent), abdominal pain (7 percent), hypertension (7 percent), and decreased ejection fraction (3 percent). The most common side effect was alopecia (52 percent), which is unique to ripretinib relative to other TKIs used for GIST.
        </p>
        <p>
         Based on these data,
         <a class="drug drug_general" data-topicid="128227" href="/z/d/drug information/128227.html" rel="external">
          ripretinib
         </a>
         is approved by the US Food and Drug Administration (FDA) for patients with advanced GIST who have received three or more TKIs, including
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         [
         <a href="#rid113">
          113
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Alternative targeted agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who are ineligible for or intolerant of
         <a class="drug drug_general" data-topicid="128227" href="/z/d/drug information/128227.html" rel="external">
          ripretinib
         </a>
         , alternative options include
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         ,
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         , or pimitespib (where available).
         <a class="drug drug_general" data-topicid="126556" href="/z/d/drug information/126556.html" rel="external">
          Avapritinib
         </a>
         is an option for those with the
         <em>
          PDGFRA
         </em>
         D842V mutation who have progressed on
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         and
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         .
        </p>
        <p>
         Limited data are available on the efficacy of these alternative TKIs to
         <a class="drug drug_general" data-topicid="128227" href="/z/d/drug information/128227.html" rel="external">
          ripretinib
         </a>
         for imatinib- and sunitinib-refractory GISTs [
         <a href="#rid75">
          75,115-125
         </a>
         ]. These agents have not been directly compared, and none are specifically approved for refractory disease. The choice between these agents is based on prior therapy, tumor mutational status, pharmacokinetics, tolerance, as well as patient and clinician preference. Patients previously treated with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         , and
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         are more likely to progress and have less durable treatment responses when these alternative agents are used beyond third-line therapy. Therefore, their use is best considered a "holding strategy," and clinical trial enrollment is encouraged, where available.
        </p>
        <p class="headingAnchor" id="H2468532544">
         <span class="h3">
          Nilotinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         For frail patients who poorly tolerated
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         , or
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         therapy,
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         may be better tolerated and, consequently, more likely to be administered at therapeutic doses. Although limited, the available data suggest that nilotinib is not an effective agent in patients whose tumors have a
         <em>
          KIT
         </em>
         exon 9 mutation [
         <a href="#rid126">
          126
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          Nilotinib
         </a>
         is a more potent second-generation TKI that targets KIT and PDGF receptors; it is not more efficacious than
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         as first-line therapy [
         <a href="#rid126">
          126
         </a>
         ], although efficacy in imatinib-refractory cases has been shown in several reports [
         <a href="#rid119">
          119,120,127
         </a>
         ]. Benefit in patients refractory to both imatinib and
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         is less certain [
         <a href="#rid121">
          121,122,125
         </a>
         ]. In a phase III trial, 248 patients with advanced GIST following prior imatinib and sunitinib failure were randomly assigned to nilotinib (400 mg twice daily) or best supportive care with or without imatinib or sunitinib [
         <a href="#rid125">
          125
         </a>
         ]. Compared with best supportive care, nilotinib improved PFS based on local investigator assessment (median 119 versus 70 days) but not when it was based on blinded central radiology review (median 109 versus 111 days).
        </p>
        <p>
         As has been shown with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         , prior gastrectomy may result in markedly lower bioavailability of a variety of other TKIs such as
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         [
         <a href="#rid128">
          128
         </a>
         ]. (See
         <a class="local">
          'Pharmacokinetic variability'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H863256033">
         <span class="h3">
          Sorafenib
         </span>
         <span class="headingEndMark">
          —
         </span>
         For those with poor tolerance of
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         alone,
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         may be helpful, given the similarity of both agents. The half-life of sorafenib is shorter than that of regorafenib, enabling more rapid resolution of toxicity and facilitating titration to the patient's own maximally tolerated dose. However, for those with disease progression on regorafenib, sorafenib is unlikely to be helpful.
        </p>
        <p>
         The efficacy of
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         (a TKI that inhibits KIT, vascular endothelial growth factor receptor [VEGFR], and platelet-derived growth factor receptor beta [PDGFRB]) was addressed in a multicenter phase II trial involving patients with either
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         (n = 6) or imatinib and sunitinib-refractory (n = 32) GIST [
         <a href="#rid116">
          116
         </a>
         ]. In preliminary results, the disease control rate was 68 percent, and median PFS was 5.2 months. The most common grade 3 toxicities were hand-foot syndrome (45 percent) and hypertension (21 percent).
        </p>
        <p class="headingAnchor" id="H3297013869">
         <span class="h3">
          Pazopanib
         </span>
         <span class="headingEndMark">
          —
         </span>
         For those with
         <em>
          KIT
         </em>
         wild-type GIST,
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         may be helpful, as it is a potent inhibitor of vascular endothelial growth factor (VEGF) signaling.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          Pazopanib
         </a>
         has activity in patients with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         and sunitinib-refractory disease [
         <a href="#rid123">
          123,124
         </a>
         ]. The efficacy of pazopanib, compared with best supportive care (BSC) alone, was addressed in a small randomized phase II PAZOGIST trial conducted in 81 patients who were refractory to imatinib and
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         [
         <a href="#rid124">
          124
         </a>
         ]. Compared with BSC alone, pazopanib improved PFS (median 3.4 versus 2.3 months, HR 0.59, 95% CI 0.37-0.96). Although there were no objective responses, 84 percent had stable disease (compared with 70 percent with BSC only). However, toxicity rates were high; among the 76 patients who eventually were treated with pazopanib (which included 36 who crossed over from the BSC group), 72 percent experienced grade ≥3 adverse events, including serious adverse events (eg, pulmonary embolism in 9 percent).
        </p>
        <p class="headingAnchor" id="H3962670756">
         <span class="h3">
          Avapritinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="126556" href="/z/d/drug information/126556.html" rel="external">
          Avapritinib
         </a>
         is an option for those patients with a
         <em>
          PDGFRA
         </em>
         D842V mutation who have progressed on
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         and
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         . In this subset of patients, avapritinib improved PFS and objective response rates (ORR) compared with
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         in a phase III trial [
         <a href="#rid129">
          129
         </a>
         ]. For other patients with a
         <strong>
          <em>
           PDGFRA
          </em>
         </strong>
         <strong>
          exon 18 mutation other than D842V,
         </strong>
         we reserve the use of avapritinib for those with disease that has progressed on all three agents (imatinib, sunitinib, and regorafenib). For all other patients with such treatment-refractory disease lacking a
         <em>
          PDGFRA
         </em>
         exon 18 mutation, including D842V, we do not suggest the use of avapritinib because it confers no additional clinical benefit compared with regorafenib and is associated with central nervous system toxicity.
        </p>
        <p>
         In an open-label phase III trial (VOYAGER), 476 patients with unresectable or metastatic GIST previously treated with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         and one or two additional TKIs were randomly assigned to either
         <a class="drug drug_general" data-topicid="126556" href="/z/d/drug information/126556.html" rel="external">
          avapritinib
         </a>
         or
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         [
         <a href="#rid129">
          129,130
         </a>
         ]. A majority of patients (95 percent) also previously received
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         , but none received regorafenib or more than three different TKIs. In the entire study population, compared with regorafenib, avapritinib improved ORR (17 versus 7 percent) but had similar PFS (median 4.2 versus 5.6 months, HR 1.25, 95% CI 0.99-1.57), disease control rates (42 versus 46 percent), and overall survival (OS) at one year (68 versus 67 percent). Among the 13 patients with
         <em>
          PDGFRA
         </em>
         D842V-mutant tumors, avapritinib improved PFS over regorafenib (median not reached versus 4.5 months) and ORR (43 versus 0 percent). In contrast, for patients without a
         <em>
          PDGFRA
         </em>
         D842V mutation, regorafenib improved PFS compared with avapritinib (median 3.9 versus 5.6 months, HR 1.34, 95% CI 1.06 to 1.69). The rates of grade ≥3 treatment-related toxicity were similar between the two treatment arms (55 versus 58 percent).
        </p>
        <p>
         The efficacy of
         <a class="drug drug_general" data-topicid="126556" href="/z/d/drug information/126556.html" rel="external">
          avapritinib
         </a>
         as initial therapy in those with the
         <em>
          PDGFRA
         </em>
         D842V mutation is discussed above. (See
         <a class="local">
          'Avapritinib for PDGFRA D842V mutant tumors'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2030140114">
         <span class="h3">
          Pimitespib
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pimitespib, a heat-shock protein 90 inhibitor, is another effective option (where available) that improves PFS and OS in patients with GIST refractory to multiple TKIs.
        </p>
        <p>
         In a randomized, double-blind phase III trial (CHAPTER-GIST-301) of 86 patients with advanced GIST refractory to
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         , and
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         , pimitespib improved PFS (median 3 versus 1 months, HR 0.51, 95% CI 0.30-0.87) and cross-over-adjusted OS (median 14 versus 8 months, HR 0.42, 95% CI 0.21-0.85) compared with placebo [
         <a href="#rid131">
          131
         </a>
         ]. Grade ≥3 toxicities included diarrhea (14 percent), anemia (5 percent), renal impairment (3 percent), and decreased appetite and malaise (2 percent each).
        </p>
        <p>
         Pimitespib is available in Japan, where it has regulatory approval for the treatment of progressive GIST [
         <a href="#rid132">
          132
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H147096075">
         <span class="h3">
          Other agents
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ponatinib
         </strong>
         –
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          Ponatinib
         </a>
         is an oral TKI with potent preclinical activity against primary
         <em>
          KIT
         </em>
         exon 11 mutations and clinically important secondary resistance mutations, including A loop mutations that are resistant to
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         and
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         [
         <a href="#rid133">
          133
         </a>
         ]. In a phase II study of ponatinib after failure of standard approved TKIs, among patients with a primary
         <em>
          KIT
         </em>
         exon 11 mutation, 11 of 22 (50 percent) had stable disease or better at 16 weeks [
         <a href="#rid134">
          134
         </a>
         ]. For patients with a primary
         <em>
          KIT
         </em>
         exon 9 mutation, 3 of 11 (27 percent) had stable disease or better at 16 weeks. This was a heavily pretreated patient group; 74 percent had four or more prior regimens.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients considered for
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         should be carefully selected because of the risk of serious arterial thrombotic events that accumulate over time, as has been seen in patients with chronic myelogenous leukemia treated with ponatinib [
         <a href="#rid135">
          135
         </a>
         ]. These findings led to more restrictive eligibility criteria and a black box warning from the FDA. (See
         <a class="medical medical_review" href="/z/d/html/14250.html" rel="external">
          "Cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'VEGFR tyrosine kinase inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dasatinib
         </strong>
         <strong>
         </strong>
         –
         <strong>
         </strong>
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          Dasatinib
         </a>
         is an active agent as well in this setting [
         <a href="#rid75">
          75,115,136
         </a>
         ]. In a phase II study of dasatinib (70 mg orally twice daily) in 50 patients with advanced GIST who were refractory to
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         , 80 percent of whom were also refractory to
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         , 12 had a partial response by Choi criteria, and this was sustained for at least eight weeks in five [
         <a href="#rid75">
          75
         </a>
         ]. Among patients with a mutation in
         <em>
          KIT
         </em>
         exon 11, median PFS and OS were 2.7 and 19.6 months, respectively; median PFS for those with a mutation in
         <em>
          PDGFRA
         </em>
         exon 18 was 22 months, and median OS was not reached. It should be noted, however, that the Choi criteria have not been validated in patients treated with any TKI beyond imatinib, and none of the above phase II trials of any TKI other than imatinib have been evaluated using Choi criteria. (See
         <a class="local">
          'RECIST versus Choi criteria'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H130170631">
         <span class="h2">
          Imatinib or sunitinib rechallenge
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who are refractory to multiple TKIs (including
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         , and
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         ) imatinib or sunitinib rechallenge is a preferred strategy over discontinuing a TKI altogether, even in the face of worsening disease burden. It is hypothesized that retreatment with imatinib or sunitinib provides inhibition of the bulk of disease clones that retain sensitivity to either drug; however, the relatively short duration of benefit suggests that TKI-resistant clones continue to progress during treatment. Data that support a modest benefit for imatinib or sunitinib retreatment are as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A Korean trial randomly assigned 81 patients with advanced GIST following failure of all available TKIs to
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         rechallenge (400 mg once daily) or placebo [
         <a href="#rid137">
          137
         </a>
         ]. Median PFS was significantly greater for those patients who received imatinib (1.8 versus 0.9 months), and the disease control rate at 12 weeks was 32 percent (versus 5 percent in the placebo group). With 93 percent of the placebo patients crossing over to active treatment, median OS was similar in both groups (8.2 versus 7.5 months in the imatinib and placebo groups, respectively).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An Italian retrospective of 82 patients with advanced GIST previously treated with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         , or
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         included 74 who were retreated with imatinib (dose 400 mg daily) and eight who were retreated with sunitinib (dose individualized according to clinician choice) [
         <a href="#rid138">
          138
         </a>
         ]. In preliminary results available in abstract form, the median time to progression in retreated patients was 5.4 months, and OS was 10.4 months. A correlation between mutational status and response rate, time to progression, or OS was not found.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1081640598">
         <span class="h1">
          INVESTIGATIONAL THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical trials may be offered to both patients with treatment-naïve disease and those who have progressed on standard therapies. Patients who are interested in clinical trials should be referred to centers of excellence specializing in the treatment of GIST.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For previously untreated patients, investigational agents include the combination of
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         plus
         <a class="drug drug_general" data-topicid="118324" href="/z/d/drug information/118324.html" rel="external">
          binimetinib
         </a>
         , an MEK inhibitor [
         <a href="#rid139">
          139
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with treatment-refractory GIST, investigational agents include immunotherapy, TKIs [
         <a href="#rid140">
          140
         </a>
         ], and combination therapies that exploit resistance pathways [
         <a href="#rid141">
          141
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4086860405">
         <span class="h1">
          ROLE OF RADIATION THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with progressive symptomatic soft tissue metastases despite treatment with multiple TKIs, radiation therapy (RT) is a reasonable option, although response rates are limited for this approach.
        </p>
        <p>
         Given the limited duration of benefit for second-line treatment with a TKI (approximately five to six months), most patients with advanced GIST will eventually require palliative care. Current treatment guidelines do not address radiotherapy as a therapeutic option or consider it only for palliation of the rare patient with painful bone metastases [
         <a href="#rid44">
          44,142
         </a>
         ]. GIST has been historically considered radiotherapy resistant or minimally responsive [
         <a href="#rid143">
          143-146
         </a>
         ], although selected patients may benefit [
         <a href="#rid147">
          147-149
         </a>
         ]. A prospective study of 25 patients progressing at intra-abdominal soft tissue or liver sites during or after TKI therapy demonstrated a low objective response rate to radiotherapy (only two [8 percent] achieved a partial remission), but 20 (80 percent) had stable target lesion size for three or more months (median duration of stabilization 16 months), and this was fourfold longer than the median time to GIST progression at any site.
        </p>
        <p class="headingAnchor" id="H1195581578">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/120170.html" rel="external">
          "Society guideline links: Gastrointestinal stromal tumors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9598965">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/17046.html" rel="external">
          "Patient education: Soft tissue sarcoma (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Impact of molecular alterations
         </strong>
         - Molecular alterations that are commonly identified in gastrointestinal stromal tumors (GISTs) include mutations in
         <em>
          KIT
         </em>
         , platelet-derived growth factor receptor alpha (
         <em>
          PDGFRA)
         </em>
         , and the family of succinate dehydrogenase (
         <em>
          SDH
         </em>
         ) genes. Other molecular alterations are less common. An assessment of mutation status in individual GISTs is advised for most patients with metastatic disease because clinical responses to systemic therapy correlate with tumor genotype and influence treatment options and prognosis. (See
         <a class="local">
          'Influence of mutations on response to therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial therapy
         </strong>
         – For patients with advanced unresectable GIST, we recommend an orally active tyrosine kinase inhibitor (TKI) as initial therapy  (
         <a class="graphic graphic_algorithm graphicRef127116" href="/z/d/graphic/127116.html" rel="external">
          algorithm 1
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          <em>
           KIT
          </em>
         </strong>
         <strong>
          mutations
         </strong>
         – For patients with
         <em>
          KIT
         </em>
         exon 11 mutations, initial treatment is with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         , typically at 400 mg daily. However, for those with
         <em>
          KIT
         </em>
         exon 9 mutations, we suggest imatinib at 800 mg daily rather than 400 mg daily (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'KIT mutations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          <em>
           PDGFRA
          </em>
         </strong>
         <strong>
          exon 18 D842V
         </strong>
         – For patients with a
         <em>
          PDGFRA
         </em>
         exon 18 D842V mutation and symptomatic and/or rapidly progressive disease, we suggest initial treatment with
         <a class="drug drug_general" data-topicid="126556" href="/z/d/drug information/126556.html" rel="external">
          avapritinib
         </a>
         rather than other TKIs or observation (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). However, for those with asymptomatic and/or indolent disease, a period of observation is preferable to immediate therapy with avapritinib to avoid treatment-related toxicities, such as potential cognitive impairment. Although avapritinib has not been directly compared with other TKIs, these tumors often demonstrate primary resistance to
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         . (See
         <a class="local">
          'Avapritinib for PDGFRA D842V mutant tumors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          <em>
           PDGFRA
          </em>
         </strong>
         <strong>
          mutation other than D842V
         </strong>
         – For patients with a
         <em>
          PDGFRA
         </em>
         mutation other than D842V, we suggest initial treatment with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         rather than other agents, given the recognized imatinib sensitivity of this subtype of GIST. (See
         <a class="local">
          'PDGFRA mutations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          SDH-deficient tumors
         </strong>
         – For patients with succinate dehydrogenase (SDH)-deficient tumors, we refer patients for clinical trials, as these tumors are minimally responsive to
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         and other agents. For those who are ineligible or who decline such trials, we offer
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         or
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         , as these agents have some limited efficacy in this setting. (See
         <a class="local">
          'SDH-deficient tumors and those associated with NF1'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Response assessment
         </strong>
         – The optimal means of response assessment in patients receiving TKIs is unclear. Radiographic response is often indicated by an early decrease in tumor density on contrast-enhanced computed tomography (CT) scan, followed by slow tumor regression. This pattern of response is not well suited to the use of standard response criteria. Because of this, TKIs should be continued indefinitely in the absence of overt radiographic progression (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'Assessing response to therapy'
         </a>
         above and
         <a class="local">
          'Duration of therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Although positron emission tomography (PET) scans appear to identify a greater number of responses and at an earlier time than CT, PET is not routinely indicated for response assessment. (See
         <a class="local">
          'Positron emission tomography scanning'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         However, one clinical scenario where baseline and follow-up PET scan might prove useful is for a patient with borderline resectable GIST or a potentially resectable tumor that requires extensive organ disruption who is being treated with initial
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         . Early assessment of treatment response provides the opportunity to shift to an alternative therapy (eg, resection or
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         ) if imatinib is ineffective. (See
         <a class="medical medical_review" href="/z/d/html/7730.html" rel="external">
          "Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors", section on 'Neoadjuvant therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role of surgery
         </strong>
         – The role of surgery in patients with locally unresectable, nonmetastatic GISTs and in those with potentially resectable metastatic disease who respond to
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         is evolving. This approach has little to offer patients with extensive disease progression while receiving imatinib. (See
         <a class="medical medical_review" href="/z/d/html/7727.html" rel="external">
          "Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract", section on 'Metastatic GIST with potentially resectable disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disease refractory to
         </strong>
         <strong>
          imatinib
         </strong>
         – For patients who are intolerant of
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         or who become refractory to treatment, we recommend a trial of the multitargeted TKI
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Thyroid function should be evaluated at baseline and monitored at frequent intervals during therapy. (See
         <a class="local">
          'Treatment of disease refractory to imatinib'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         An alternative approach, increasing the dose of
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         to 800 mg daily, may be useful in patients who have clearly progressive disease while receiving 400 mg daily doses and who are tolerating the drug reasonably well. However, this approach is unlikely to benefit patients who have primary resistance to treatment (eg, within two months) after starting therapy. (See
         <a class="local">
          'Dose escalation of imatinib'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disease refractory to
         </strong>
         <strong>
          imatinib
         </strong>
         <strong>
          and
         </strong>
         <strong>
          sunitinib
         </strong>
         – For patients with imatinib- and sunitinib-refractory GIST, we recommend
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         rather than other TKIs (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'Treatment of disease refractory to imatinib and sunitinib'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disease refractory to
         </strong>
         <strong>
          imatinib
         </strong>
         <strong>
          ,
         </strong>
         <strong>
          sunitinib
         </strong>
         <strong>
          , and
         </strong>
         <strong>
          regorafenib
         </strong>
         – For patients with GIST (irrespective of
         <em>
          PDGFRA
         </em>
         D842V mutation status) refractory to or intolerant of
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         , and
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         , we suggest the use of
         <a class="drug drug_general" data-topicid="128227" href="/z/d/drug information/128227.html" rel="external">
          ripretinib
         </a>
         over other available TKIs (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Treatment of disease refractory to imatinib, sunitinib, and regorafenib'
         </a>
         above and
         <a class="local">
          'Ripretinib'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For those who are ineligible for or intolerant of
         <a class="drug drug_general" data-topicid="128227" href="/z/d/drug information/128227.html" rel="external">
          ripretinib
         </a>
         , options include
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         ,
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         , pimitespib (where available), or rechallenge with either
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         or
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         .
         <a class="drug drug_general" data-topicid="126556" href="/z/d/drug information/126556.html" rel="external">
          Avapritinib
         </a>
         is an option for patients with the
         <em>
          PDGFRA
         </em>
         D842V mutation who have progressed on imatinib and sunitinib. (See
         <a class="local">
          'Alternative targeted agents'
         </a>
         above and
         <a class="local">
          'Imatinib or sunitinib rechallenge'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role of radiation therapy
         </strong>
         – For patients with progressive symptomatic soft tissue metastases despite treatment with multiple TKIs, radiation therapy is a reasonable option. (See
         <a class="local">
          'Role of radiation therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4213042121">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges George Demetri, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Rubin BP, Fletcher JA, Fletcher CD. Molecular Insights into the Histogenesis and Pathogenesis of Gastrointestinal Stromal Tumors. Int J Surg Pathol 2000; 8:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demetri GD, Elias AD. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Hematol Oncol Clin North Am 1995; 9:765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plaat BE, Hollema H, Molenaar WM, et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000; 18:3211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edmonson JH, Marks RS, Buckner JC, Mahoney MR. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest 2002; 20:605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balachandran VP, Cavnar MJ, Zeng S, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011; 17:1094.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344:1052.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358:1421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Oosterom AT, Judson IR, Verweij J, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002; 38 Suppl 5:S83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364:1127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26:626.
          </a>
         </li>
         <li class="breakAll">
          von Mehren M, Heinrich MC, Joensuu H, et al. Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST) (abstract 10016). J Clin Oncol 2011; 29:609s. Abstract available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=102&amp;abstractID=82574 (Accessed on July 19, 2011).
         </li>
         <li class="breakAll">
          Demetri GD, Rankin CJ, Benjamin RS, et al. Long-term disease control of advanced gastrointestinal stromal tumors with imatinib: 10-year otcoms from SWOG phase III intergroup trial S0033 (abstract). J Clin Oncol 32:5s (suppl; abstract 10508). Abstract available online at: http://meetinglibrary.asco.org/content/134128-144 (Accessed on July 07, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26:620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Glabbeke M, Verweij J, Casali PG, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 2005; 23:5795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rutkowski P, Nowecki ZI, Debiec-Rychter M, et al. Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs). J Cancer Res Clin Oncol 2007; 133:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Armbrust T, Sobotta M, Gunawan B, et al. Does imatinib turn recurrent and/or metastasized gastrointestinal stromal tumors into a chronic disease? - single center experience. Eur J Gastroenterol Hepatol 2009; 21:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heinrich MC, Rankin C, Blanke CD, et al. Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 2017; 3:944.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kristensen CA, Eigtved A, Bjerregard B, et al. FDG-PET versus spiral CT for evaluation of STI571 treatment of gastrointestinal stromal tumors (abstract). Proc Am Soc Clin Oncol 2003; 22:824a.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stroobants S, Goeminne J, Seegers M, et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003; 39:2012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antoch G, Kanja J, Bauer S, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004; 45:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van den Abbeele AD. The lessons of GIST--PET and PET/CT: a new paradigm for imaging. Oncologist 2008; 13 Suppl 2:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van den Abbeele AD, Gatsonis C, de Vries DJ, et al. ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression. J Nucl Med 2012; 53:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shankar LK, Hoffman JM, Bacharach S, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006; 47:1059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 2015; 42:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O JH, Lodge MA, Wahl RL. Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. Radiology 2016; 280:576.
          </a>
         </li>
         <li class="breakAll">
          National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on July 25, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bechtold RE, Chen MY, Stanton CA, et al. Cystic changes in hepatic and peritoneal metastases from gastrointestinal stromal tumors treated with Gleevec. Abdom Imaging 2003; 28:808.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linton KM, Taylor MB, Radford JA. Response evaluation in gastrointestinal stromal tumours treated with imatinib: misdiagnosis of disease progression on CT due to cystic change in liver metastases. Br J Radiol 2006; 79:e40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LeCesne A, van Glabbeke M, Verweij J, et al. Is stable disease according to RECIST criteria a real stable disease in GIST patients treated with imatinib mesylate included in the intergroup EORTC/ISG/AGITG trial? (abstract). J Clin Oncol 2006; 24:522s.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Cesne A, Van Glabbeke M, Verweij J, et al. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol 2009; 27:3969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shankar S, vanSonnenberg E, Desai J, et al. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology 2005; 235:892.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dileo P, Randhawa R, Vansonnenberg E, et al. Safety and efficacy of percutaneous radio-frequency ablation in patients with metastatic gastrointestinal stromal tumors (GIST) with clonal evolution of lesions refractory to imatinib mesylate (abstract). Proc Am Soc Clin Oncol 2004; 22:820a.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25:1753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007; 25:1760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 2010; 28:1247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 2009; 27:3141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoo C, Ryu MH, Kang BW, et al. Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. J Clin Oncol 2010; 28:1554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eechoute K, Sparreboom A, Burger H, et al. Drug transporters and imatinib treatment: implications for clinical practice. Clin Cancer Res 2011; 17:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Judson I, Ma P, Peng B, et al. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 2005; 55:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eechoute K, Fransson MN, Reyners AK, et al. A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res 2012; 18:5780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casali PG, Abecassis N, Aro HT, et al. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29:iv267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007; 5 Suppl 2:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21:4342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004; 40:689.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005; 23:5357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008; 26:5360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patrikidou A, Domont J, Chabaud S, et al. Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group. Eur J Cancer 2016; 52:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42:1093.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cassier PA, Fumagalli E, Rutkowski P, et al. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res 2012; 18:4458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoo C, Ryu MH, Jo J, et al. Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors. Cancer Res Treat 2016; 48:546.
          </a>
         </li>
         <li class="breakAll">
          Farag S, Somaiah N, Chooi H, et al. Clinical characteristics and treatment outcome in a large multicenter observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumor (GIST) patients (abstract). J Clin Oncol 34, 2016 (suppl; abstr 11011). Abstract available online at http://meetinglibrary.asco.org/content/164473-176 (Accessed on June 16, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004; 28:889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003; 125:660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 2007; 25:1107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patrikidou A, Chabaud S, Ray-Coquard I, et al. Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. Ann Oncol 2013; 24:1087.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003; 39:2006.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim EJ, Ryu MH, Park SR, et al. Systemic Steroid Treatment for Imatinib-Associated Severe Skin Rash in Patients with Gastrointestinal Stromal Tumor: A Phase II Study. Oncologist 2020; 25:e1785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Glabbeke M, Verweij J, Casali PG, et al. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). Eur J Cancer 2006; 42:2277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006; 354:2006.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joensuu H, Reichardt P. Imatinib and altered bone and mineral metabolism. N Engl J Med 2006; 355:628; author reply 628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Owen S, Hatfield A, Letvak L. Imatinib and altered bone and mineral metabolism. N Engl J Med 2006; 355:627; author reply 628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrero D, Pogliani EM, Rege-Cambrin G, et al. Corticosteroids can reverse severe imatinib-induced hepatotoxicity. Haematologica 2006; 91:ECR27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kerkelä R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12:908.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verweij J, Casali PG, Kotasek D, et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. Eur J Cancer 2007; 43:974.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trent JC, Patel SS, Zhang J, et al. Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Cancer 2010; 116:184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rutkowski P, Ruka W. Emergency surgery in the era of molecular treatment of solid tumours. Lancet Oncol 2009; 10:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joseph CP, Abaricia SN, Angelis MA, et al. Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors. Oncologist 2021; 26:e622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heinrich MC, Jones RL, von Mehren M, et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol 2020; 21:935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones RL, Serrano C, von Mehren M, et al. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. Eur J Cancer 2021; 145:132.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration (FDA) Label for Avapritinib. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212608s000lbl.pdf (Accessed on January 14, 2020).
         </li>
         <li class="breakAll">
          Trent JC, et al. A phase II study of dasatanib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST) (Abstract 10006). J Clin Oncol 2011; 29:604s. Abstract available online at http://meetinglibrary.asco.org/content/79120-102 (Accessed on July 19, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schuetze SM, Bolejack V, Thomas DG, et al. Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib. JAMA Oncol 2018; 4:814.
          </a>
         </li>
         <li class="breakAll">
          von Mehren M, Tetzlaff ED, Macaraeg M, et al. Dose escalating study of crenolanib besylate in advanced GIST patients with PDGFRA D842V activating mutations (abstract). J Clin Oncol 34, 2016 (suppl; abstr 11010). Abstract available online at http://meetinglibrary.asco.org/content/170566-176 (Accessed on June 16, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boikos SA, Pappo AS, Killian JK, et al. Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncol 2016; 2:922.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glod J, Arnaldez FI, Wiener L, et al. A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor. Clin Cancer Res 2019; 25:6302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mussi C, Schildhaus HU, Gronchi A, et al. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. Clin Cancer Res 2008; 14:4550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005; 41:1751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tamborini E, Bonadiman L, Greco A, et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 2004; 127:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen LL, Trent JC, Wu EF, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004; 64:5913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005; 11:4182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wardelmann E, Merkelbach-Bruse S, Pauls K, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 2006; 12:1743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006; 24:4764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liegl B, Kepten I, Le C, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 2008; 216:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serrano C, Mariño-Enríquez A, Tao DL, et al. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. Br J Cancer 2019; 120:612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guo T, Agaram NP, Wong GC, et al. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res 2007; 13:4874.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005; 128:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demetri GD, Heinrich MC, Fletcher JA, et al. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res 2009; 15:5902.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008; 26:5352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368:1329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rutkowski P, Bylina E, Klimczak A, et al. The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study. BMC Cancer 2012; 12:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demetri GD, Garrett CR, Schöffski P, et al. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clin Cancer Res 2012; 18:3170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reichardt P, Kang YK, Rutkowski P, et al. Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib. Cancer 2015; 121:1405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reichardt P, Demetri GD, Gelderblom H, et al. Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. BMC Cancer 2016; 16:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prior JO, Montemurro M, Orcurto MV, et al. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol 2009; 27:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009; 45:1959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guo T, Hajdu M, Agaram NP, et al. Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clin Cancer Res 2009; 15:6862.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Desai J, Yassa L, Marqusee E, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006; 145:660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolter P, Stefan C, Decallonne B, et al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer 2008; 99:448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370:2011.
          </a>
         </li>
         <li class="breakAll">
          Raut CP. Morgan JA, Quigley MT, et al. Perioperative sunitinib dosing around extensive resections of imatinib-resistant metastatic gastrointestinal stromal tumors (abstract 10044). J Clin Oncol 2007; 25:555s. Abstract available online at: http://www.asco.org/ascov2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=47&amp;abstractID=36307 (Accessed on July 19, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bauer S, Jones RL, Blay JY, et al. Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial. J Clin Oncol 2022; 40:3918.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heinrich MC, Jones RL, George S, et al. Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial. Nat Med 2024.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ben-Ami E, Barysauskas CM, von Mehren M, et al. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Ann Oncol 2016; 27:1794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           George S, Wang Q, Heinrich MC, et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol 2012; 30:2401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blay JY, Serrano C, Heinrich MC, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2020; 21:923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janku F, Abdul Razak AR, Chi P, et al. Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. J Clin Oncol 2020; 38:3294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zalcberg JR, Heinrich MC, George S, et al. Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study. Oncologist 2021; 26:e2053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           George S, Chi P, Heinrich MC, et al. Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. Eur J Cancer 2021; 155:236.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration Label for ripretinib. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213973s001lbl.pdf (Accessed on July 07, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bauer S, Heinrich MC, George S, et al. Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study. Clin Cancer Res 2021; 27:6333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dewaele B, Wasag B, Cools J, et al. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res 2008; 14:5749.
          </a>
         </li>
         <li class="breakAll">
          Kindler H, Campbell NP, Wroblewski K, et al. Final results of a University of Chicago phase II consortium trial of sorafenib (SOR) in patients (pts) with imatinib (IM)- and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST) (abstract). Data presented at the 2011 ASCO GI Cancers Symposium, January 20-22, San Francisco, CA. Abstract available online at https://ascopubs.org/doi/abs/10.1200/jco.2011.29.15_suppl.10009 (Accessed on April 27, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park SH, Ryu MH, Ryoo BY, et al. Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. Invest New Drugs 2012; 30:2377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montemurro M, Gelderblom H, Bitz U, et al. Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis. Eur J Cancer 2013; 49:1027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montemurro M, Schöffski P, Reichardt P, et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer 2009; 45:2293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sawaki A, Nishida T, Doi T, et al. Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer 2011; 117:4633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cauchi C, Somaiah N, Engstrom PF, et al. Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib. Cancer Chemother Pharmacol 2012; 69:977.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanda T, Ishikawa T, Takahashi T, Nishida T. Nilotinib for treatment of gastrointestinal stromal tumors: out of the equation? Expert Opin Pharmacother 2013; 14:1859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ganjoo KN, Villalobos VM, Kamaya A, et al. A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib. Ann Oncol 2014; 25:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mir O, Cropet C, Toulmonde M, et al. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. Lancet Oncol 2016; 17:632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reichardt P, Blay JY, Gelderblom H, et al. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol 2012; 23:1680.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blay JY, Shen L, Kang YK, et al. Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. Lancet Oncol 2015; 16:550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demetri GD, Casali PG, Blay JY, et al. A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res 2009; 15:5910.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim KP, Ryu MH, Yoo C, et al. Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. Cancer Chemother Pharmacol 2011; 68:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kang YK, George S, Jones RL, et al. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. J Clin Oncol 2021; 39:3128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serrano C, Bauer S, Gómez-Peregrina D, et al. Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib. Ann Oncol 2023; 34:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurokawa Y, Honma Y, Sawaki A, et al. Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol 2022; 33:959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoy SM. Pimitespib: First Approval. Drugs 2022; 82:1413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garner AP, Gozgit JM, Anjum R, et al. Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. Clin Cancer Res 2014; 20:5745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heinrich MC, vonMehren M, Demetri GD, et al. A phase 2 study of ponatinib in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after failure of tyrosine kinase inhibitor (TKI) therapy: Initial report. Ann Oncol 2014; 24(Suppl 4):iv494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013; 369:1783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montemurro M, Cioffi A, Dômont J, et al. Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07). Cancer 2018; 124:1449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kang YK, Ryu MH, Yoo C, et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2013; 14:1175.
          </a>
         </li>
         <li class="breakAll">
          Vincenzi B, Nannini M, Grignani G, et al. Rechallenge in advanced GIST progressing to imatinib, sunitinib and regorafenib: An Italian survey (abstract). J Clin Oncol 35, 2017 (suppl; abstr 11038). Abstract available online at http://abstracts.asco.org/199/AbstView_199_187477.html (Accessed on July 12, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chi P, Qin LX, Nguyen B, et al. Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. J Clin Oncol 2022; 40:997.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schöffski P, Mir O, Kasper B, et al. Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'. Eur J Cancer 2020; 134:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagner AJ, Severson PL, Shields AF, et al. Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial. JAMA Oncol 2021; 7:1343.
          </a>
         </li>
         <li class="breakAll">
          Consensus-based guidelines from the National Comprehensive Cancer Network (NCCN) available online at http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed on November 02, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           von Mehren M. Imatinib-refractory gastrointestinal stromal tumors: the clinical problem and therapeutic strategies. Curr Oncol Rep 2006; 8:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sawaki A, Yamao K. Imatinib mesylate acts in metastatic or unresectable gastrointestinal stromal tumor by targeting KIT receptors--a review. Cancer Chemother Pharmacol 2004; 54 Suppl 1:S44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schnadig ID, Blanke CD. Gastrointestinal stromal tumors: imatinib and beyond. Curr Treat Options Oncol 2006; 7:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pierie JP, Choudry U, Muzikansky A, et al. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 2001; 136:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corbin KS, Kindler HL, Liauw SL. Considering the role of radiation therapy for gastrointestinal stromal tumor. Onco Targets Ther 2014; 7:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cuaron JJ, Goodman KA, Lee N, Wu AJ. External beam radiation therapy for locally advanced and metastatic gastrointestinal stromal tumors. Radiat Oncol 2013; 8:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joensuu H, Eriksson M, Collan J, et al. Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: A prospective study. Radiother Oncol 2015; 116:233.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7725 Version 90.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11493959" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Molecular Insights into the Histogenesis and Pathogenesis of Gastrointestinal Stromal Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7490240" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10986053" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12197215" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21873989" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11287975" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11705489" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12181401" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12528778" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15451219" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18235122" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18235122" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18235122" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18235121" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16110036" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17458563" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19369884" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Does imatinib turn recurrent and/or metastasized gastrointestinal stromal tumors into a chronic disease? - single center experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28196207" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : FDG-PET versus spiral CT for evaluation of STI571 treatment of gastrointestinal stromal tumors (abstract)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12957455" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15001674" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18434632" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The lessons of GIST--PET and PET/CT: a new paradigm for imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22381410" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16741317" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25452219" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26909647" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26909647" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14753595" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Cystic changes in hepatic and peritoneal metastases from gastrointestinal stromal tumors treated with Gleevec.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16861316" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Response evaluation in gastrointestinal stromal tumours treated with imatinib: misdiagnosis of disease progression on CT due to cystic change in liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Is stable disease according to RECIST criteria a real stable disease in GIST patients treated with imatinib mesylate included in the intergroup EORTC/ISG/AGITG trial? (abstract)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19620483" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19097774" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10655437" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15833985" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Safety and efficacy of percutaneous radio-frequency ablation in patients with metastatic gastrointestinal stromal tumors (GIST) with clonal evolution of lesions refractory to imatinib mesylate (abstract)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17470865" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17470866" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : We should desist using RECIST, at least in GIST.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20124181" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19451435" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20177019" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21163869" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Drug transporters and imatinib treatment: implications for clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15592836" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22850565" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30188977" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17624289" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14645423" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15010069" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15928335" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18955451" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26687836" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16624552" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22718859" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26130666" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26130666" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15223958" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12949711" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17369574" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23175622" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12957454" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32589310" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Systemic Steroid Treatment for Imatinib-Associated Severe Skin Rash in Patients with Gastrointestinal Stromal Tumor: A Phase II Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16876399" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16687713" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Altered bone and mineral metabolism in patients receiving imatinib mesylate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16903020" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Imatinib and altered bone and mineral metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16899786" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Imatinib and altered bone and mineral metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16785130" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Corticosteroids can reverse severe imatinib-induced hepatotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16862153" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17336514" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19885836" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19185833" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Emergency surgery in the era of molecular treatment of solid tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33301227" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32615108" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33465704" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33465704" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33465704" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29710216" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29710216" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27011036" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31439578" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18628470" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16098458" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15236194" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15342366" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15930355" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16551858" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16954519" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18623623" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Heterogeneity of kinase inhibitor resistance mechanisms in GIST.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30792533" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17699867" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15685537" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19737946" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18955458" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17046465" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22439647" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22661587" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25641662" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26772734" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19064982" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19282169" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19861442" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17088579" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18665181" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18083403" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18083403" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35947817" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/38182785" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23177515" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27371698" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22614970" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32511981" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32804590" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34313371" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34391056" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34391056" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34503977" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18794084" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18794084" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22270258" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23140824" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19467857" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21456006" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22119758" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23834614" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Nilotinib for treatment of gastrointestinal stromal tumors: out of the equation?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24356634" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27068858" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22357255" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25882987" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19723647" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20957481" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34343033" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37105265" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35688358" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35986838" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Pimitespib: First Approval.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25239608" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : A phase 2 study of ponatinib in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after failure of tyrosine kinase inhibitor (TKI) therapy: Initial report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24180494" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29315500" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24140183" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24140183" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35041493" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32470848" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34236401" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34236401" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16618383" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Imatinib-refractory gastrointestinal stromal tumors: the clinical problem and therapeutic strategies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15309514" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Imatinib mesylate acts in metastatic or unresectable gastrointestinal stromal tumor by targeting KIT receptors--a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17032555" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Gastrointestinal stromal tumors: imatinib and beyond.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11296107" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : The effect of surgery and grade on outcome of gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24872712" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Considering the role of radiation therapy for gastrointestinal stromal tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24267287" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : External beam radiation therapy for locally advanced and metastatic gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26228971" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: A prospective study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
